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Lysophosphatidic acid (LPA), a naturally occurring phospholipid present in serum 
and malignant effusions, elicits diverse biological functions through binding and activating 
specific cell surface G-protein coupled receptors. In addition to the conventional 
LPA1/Edg2, LPA2/Edg4 and LPA3/Edg7 receptors of the endothelial differentiation gene 
(Edg) family, LPA4/p2y9/GPR23 of the purinergic receptor family and the related 
LPA5/GPR92 and LPA6/p2y5 have been identified as novel LPA receptors. These newly 
identified LPA receptors are structurally distant from the Edg LPA1-3 receptors and couple 
to Gq, G12/13 and probably Gs subunits. However, the roles of the LPA4-6 receptors in LPA 
xvi 
 
signal transduction and physiology are poorly understood. This project has used 
biochemical and genetic approaches to study biological functions of LPA4.  
In the first part of the study, we confirmed that LPA4 is indeed a functional LPA 
receptor mediating some cellular and biochemical responses to LPA including stimulation 
of neurite retraction, protein tyrosine phosphorylation. LPA4 also physically binds to LPA 
when ectopically expressed in cell lines.  
Mammalian cells usually express multiple LPA receptor subtypes and respond to 
LPA, making it difficult to link LPA receptors to specific responses. Targeted deletion has 
become a necessary approach to probe functions of individual LPA receptors. We therefore 
disrupted LPA4-encoding gene (lpa4/p2y9/gpr23) in mice. LPA4-deficient mice were born 
at the expected frequency and displayed no apparent abnormalities at least at early ages, 
indicating that LPA4 is not required for fertility, embryonic development or normal 
physiology. This is similar to knockouts of other LPA receptors. The backup and/or 
redundant receptor subtypes of LPA may suffice to compensate for the loss of individual 
LPA receptors in vivo. Alternatively, LPA may not be the only or rate-limiting mediator 
physiologically required in vivo. LPA signaling may be more critical in pathophysiological 
conditions when levels of the lipid mediator are locally and temporally altered. The 
availability of LPA4-null mice provides a valued model to analyze the roles of LPA4 in 
pathophysiological processes. 
Despite the lack of apparent phenotypes in mice, we took advantage of the LPA4-
negative mouse embryonic fibroblasts (MEFs) to evaluate the effects of lpa4 deletion on 
cellular responses to LPA. Strikingly, LPA4-deficient MEFs were hypersensitive to LPA-
xvii 
 
induced migration. Consistent with negative modulation of the phosphatidylinositol 3 
kinase (PI3K) pathway by LPA4, LPA4 deficiency potentiated AKT and Rac but decreased 
Rho activation induced by LPA. Reconstitution of LPA4 converted LPA4-negative cells 
into a less motile phenotype. In support of the biological relevance of these observations, 
ectopic expression of LPA4 strongly inhibited migration and invasion of human cancer 
cells. When coexpressed with LPA1 in B103 neuroblastoma cells devoid of endogenous 
LPA receptors, LPA4 attenuated LPA1-driven migration and invasion, indicating functional 
antagonism between the two subtypes of LPA receptors. These results provide genetic and 
biochemical evidence that LPA4 is a suppressor of LPA-dependent cell migration and 
invasion. LPA4 may thus play a role in negative regulation of LPA signal transduction and 
specific cellular responses.  
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CHAPTER 1: GENERAL INTRODUCTION 
 
Lysophosphatidic acid (LPA) 
In the past decade, there have been considerable advances in our understanding of 
the sources and biological roles of lysophospholipids. The best characterized of these are 
LPA with a glycerol backbone and the related sphingosine-1-phosphate (S1P) containing 
sphingosine (Fig. 1-1). These lysophospholipids are not only metabolites in biosynthesis of 
more complex lipids in eukaryotic and prokaryotic cells but also have emerged as 
pluropotent intercellular mediators to induce hormone- and growth factor-like responses in 
their target cells through activation of specific G protein-coupled receptors. 
LPA is the simplest lysophospholipid made up of a glycerol backbone with a 
phosphate group, and a long saturated or unsaturated fatty acyl chain (Fig.1-1). It is unique 
from the other lysophospholipids because it lacks a head group attached to its phosphate 
moiety, such as the choline head group in lysophosphatidylcholine. Despite its simple 
structure, LPA, which was originally considered as a precursor and component of lipid 
remodeling, is now widely known to be an important extracellular mediator of a broad 
variety of biological processes by binding to its cognate G protein-coupled receptors 
(GPCRs) (1). The most prominent cellular effects of LPA include stimulation of cell 
proliferation, survival (2), migration (3,4), cytoskeleton remodeling (5,6) in both normal 
and neoplastice cells. LPA is also involved in control of adipogenesis and obesity by 
stimulating proliferation of pre-adipocytes through LPA1 thereby inhibiting its maturation 
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to fat cells (7-9). As a bioactive constituent of mildly oxidized LPL and atherosclerotic 
lesions (10), LPA has been postulated to play a role in the pathogenesis of atherosclerosis 
particularly through its activity on other vascular effect such as stimulation of monocyte 
attachment to blood vessel walls (11), plaque formation (12), increased endothelial 
permeability (13,14) and promotion of vascular smooth muscle cells dedifferentiation (15). 
Most importantly, LPA induces progressive formation of neointima in a rat carotid artery 
model (16,17). These findings suggest that LPA may act as an endogenous atherogenic 
factor in vivo. Recent studies demonstrate that LPA modulates expression of many 
paracrine growth factors including those involved in inflammation, angiogenesis and tumor 
progression such as interleukin 6 (IL-6), interleukin 8 (IL-8), growth regulated oncogene α 
(GROα), cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF), 
urokinase plasminogen activator (uPA) (18-24). LPA may thus promote tumorigenesis by 
upregulating its target genes to create a more invasive and metastatic microenvironment 
for tumor cells.  
.  
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Figure 1-1. Chemical structures of the bioactive lysophosphatidic acid (LPA) and its 
related sphingosine-1-phosphate (S1P).  
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LPA Biosynthesis and Metabolism 
LPA is produced and secreted by activated platelets in response to either 
coagulation or wound healing, thus LPA is a active constituent of serum and present at 
physiologically relevant concentrations in an albumin-bound form (25-29). The 
physiological concentrations of LPA in serum range from approximately 1 to 10 μM. LPA 
is also rich in body fluids such as saliva, follicular fluids and malignant effusions (30-33). 
In ascites of ovarian cancer patients, the levels of LPA reach 80 μM. Ovarian tumor cells 
have the ability to synthesize and secrete LPA, which may contribute to the high levels of 
LPA accumulated in ascites of ovarian cancer patients (33,34). LPA can also be produced 
by other cell types such as adipocytes, fibroblasts, endothelial cells, and leukocytes (35). 
Extracellular lipoprotein oxidation of LDL can also lead to production of LPA (10).  
The molecular pathways for extracellular LPA production have been best 
characterized in activated platelets that are responsible for increased LPA levels in serum 
compared to the whole blood or plasma. LPA can be produced by activated platelets from 
newly generated, membrane associated PA by the action of phospholipase D followed by 
phospholipase A1 or A2 -mediated deacylation (28). However, the bulk of LPA arising 
from platelet activation results from the sequential cleavage of serum and membrane 
phospholipids to lysophospholipids by PLA1 and PLA2 secreted by platelets (27,28), 
followed by conversion to LPA by lysophospholipase D (LysoPLD) present in the plasma 
(11,27). It has been long known that plasma contains prominent LysoPLD activity, 
contributing to ongoing production of LPA from lysophosphatidylcholine (LPC) during 
cell culture (27,29). The plasma LysoPLD was recently identified to be autotaxin (ATX) 
5 
 
(3,11), a member of the nucleotide pyrophosphatase and phosphodiesterase family of exo- 
and ecto-enzymes (36). Homozygous deletion of ATX leads to embryonic lethality at E9.5 
due to impaired vessel formation in the yolk sac and embryo proper (37,38), indicating that 
ATX is essential for embryonic vasculature. The results also imply that ATX is necessary 
for LPA biosynthesis at least during embryo development. ATX, a 125 kDa glycoprotein 
was first isolated in 1992 as an autocrine motility-stimulating factor for human melanoma 
cells (39). Now, it has become clear that ATX promotes cell migration and invasion via 
formation and action of LPA (40,41). 
LPC, the major physiological substrate of ATX, is secreted by the liver and 
circulate at high concentration level (>100 μM) in the blood in an albumin-bound form 
(35,42). The precursor of LPC, PC is also abundant in the plasma reaching approximately 
1 mM (35). Despite the high concentrations of LPA precursors in the blood stream, LPA 
concentrations in the plasma are maintained at low levels under physiological conditions. 
This could be explained by the fact that ATX catalyzing activity is inhibited by multiple 
factors including its product LPA (negative feedback), certain amino acids and other blood 
constituents (43). 
LPA can be metabolized through acylation of the sn-2 hydroxyl group by LPA acyl 
transferases such as endophilin (44), deacylated by lysophospholipases to produce glycerol 
phosphate (45), or dephosphorylated by lipid phosphate phosphohydrolases (LPP) 
including LPP1/PAP2A, LPP3/PAP2B and LPP2/PAP2C to generate monoacylglycerol 
(46-49) (Fig. 1-2). LPPs are located at the cell membrane with the catalytic domain facing 
the extracellular media. The enzymes degrade LPA associated with the external leaflet of 
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the membrane (50). Overexpression of LPPs has been shown to antagonize cellular 
responses to LPA and reduce LPA concentrations in the medium (50). In contrast, 
inhibition of LPP enzyme activity sensitizes platelets to LPA-induced responses as well as 
increases thrombin-induced LPA production (51). Overall, these observations suggests 
LPPs play a critical role in controlling extracellular levels of LPA or membrane accessible 
LPA. 
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Figure 1-2. Regulation of LPA levels in the extracellular environment by ATX and 
LPPs. Secreted ATX/lysoPLD hydrolyzes carrier-bound and membrane-associated LPC to 
generate LPA. Newly produced LPA acts on its G protein–coupled receptors and thereby 
evokes numerous cellular responses. Excess LPA is converted into monoacylglycerol 
(MAG) by membrane-bound lipid phosphatases (LPPs).  
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The LPA Receptors  
The biological actions of LPA are mediated by a number of G protein-coupled 
receptor(s) (GPCRs) (1). To date, six cell surface GPCRs named LPA1-6 have been 
identified as the receptors for LPA (1,5,52-56). Based on the amino acid homology (57), 
the LPA receptor family can be divided into two subfamilies: one is composed of the first 
three LPA receptors: LPA1-3 of the Edg family, and the other consists of 
LPA4/p2y9/GPR23, LPA5/GPR92 and LPA6/p2y5. LPA1-3 share about 50-57% amino acid 
sequences similarity, with their C-terminal tails being most divergent (5,52,53). The other 
GPCRs of the Edg family are receptors for the related S1P (58). Three novel LPA 
receptors, LPA4-6 are structurally distant from the canonical Edg LPA receptors 
(54,55,59,60). LPA4 and LPA6 are members of the purinergic receptor family. They are 
closely related to the nucleotide receptors P2Y1, P2Y4 and P2Y6 (61). LPA5 belongs to 
the purinocluster of GPCRs which consist of the formyl peptide receptors (FPRs), 
receptors for nucleotides (P2Ys), thrombin, and leukotriene and a large number of orphan 
receptors. LPA4-6 display around 31% homology whereas only shares 21.3% - 22.6% 
homology with the Edg LPA receptors (54-56). Since the sequence identity within this 
purin receptor branch is generally low (~20%), LPA4-6 considered to be highly related. 
Thus LPA receptors are derived from two different ancestor genes.  
The first cDNA encoding a functional LPA receptor, now referred exclusively as 
LPA1/Edg2, was cloned from mouse cortical neuroblast cell lines in 1996 (5). It was 
named ventricular zone gene-1 (vzg-1) because of its predominant expression in the 
neurogenic ventricular zone of the embryonic cortex. Among the LPA receptors, LPA1 is 
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the best characterized subtype and most widely expressed in almost all mammalian tissues 
with the exception of livers (1,62). In some cell lineages, LPA1 is the major regulator of 
cell motility by triggering Rac and Rho dependent cytoskeleton changes. LPA1-deficient 
mice showed partial postnatal lethal (~50%) partly due to a suckling defect resulting from 
impaired olfaction (63). However, these animals proved to be valued models to study LPA 
signaling in pathophysiological conditions. This has led to identification of novel roles for 
LPA1 in the initiation of neuropathic pain and formation of pulmonary and renal fibrosis 
(64-66). In addition, LPA signaling in LPA1-/- MEFs was significantly compromised or 
abolished (62).  
 LPA2/Edg4 and LPA3/Edg7 were identified as LPA receptors following the 
discovery of the LPA1 receptor. (52,53). Gene structure analysis indicates that all three 
Edg LPA receptors contain the conserved introns in transmembrane domain six (67-69). 
Despite high homology among them, LPA1-3 have distinct tissue distribution and functions. 
For example, LPA2 shows more restricted expression in adult tissues compared to LPA1 
(70). LPA2 is frequently overexpressed in human cancers such as ovary, breast, colon, 
pancreas and thyroid cancers (19,33,71-77). It should be noted that the first reported 
human lpa2 clone was derived from an ovarian tumor library (52) and contained a frame-
shift mutation that produced 31 extra amino acids at its intracellular carboxyl terminal end, 
which could produce a gain of function mutant (78). Several 3'-untranslated region (UTR) 
variants of the lpa2 transcripts have been found in some tumors, suggesting oncogenic 
potential may be conferred by altered LPA2 stability/signaling (69). Targeted deletion of 
lpa2 in mice does not have obvious phenotypes (79). However, significant attenuation of 
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LPA signaling (e.g. PLC activation, Ca2+ mobilization, and stress fiber formation) was 
observed in primary cultures of MEFs (79). The lpa1 lpa2 double-null mice do not show 
additional phenotypic abnormalities beyond those attributable to lpa1(-/-) except for an 
increased incidence of perinatal frontal hematoma (79). However many LPA-induced 
responses including cell proliferation, adenyl cyclase activation, PLC activation, Ca2+ 
mobilization, JNK and AKT activation, and stress fiber formation, were absent or severely 
reduced in double-null MEFs (79). All these responses were only partially affected in 
MEFs lacking either LPA1 or LPA2 (79). These results indicate that LPA2 may act 
redundantly with LPA1 to mediate most LPA responses.  
Expression of LPA3 is hardly detectable in most adult tissues (70). However, 
similar to LPA2, LPA3 expression is elevated in malignancies including prostate, ovarian 
and pancreatic cancers (77,80-82). Targeted deletion of lpa3 in mice results in delayed 
implantation and altered embryo spacing (83). This could be caused by the downregulation 
of COX-2 in uterine. Implantation defect could be partially rescued by exogenous 
administration of PGE2 into lpa3 deficient female mice. The phenotype of lpa3 KO mice is 
similar to that of cPLA2α knockout mice, suggesting a critical role of LPA3 in regulation of 
COX-2 expression and PGE2 production in the female reproductive system.  
The LPA4-6 receptors are poorly characterized compared to the Edg LPA receptors. 
(54-56). None of these receptors have been knockout in mice. LPA4 is expressed at modest 
levels in majority of the tissues including heart, skeleton muscle, testis, ovary and 
embryonic stem cells (59). LPA5 is highly expressed in small intestines, sensory dorsal 
11 
 
root ganglia as well as embryonic stem cells (55). LPA6 is required for maintenance of 
human hair growth and mutated in hypotrichosis simplex (56). 
In addition to these cell surface GPCRs, LPA has been shown to bind and activate 
the peroxisome proliferator–activated receptor γ (PPARγ) which plays critical roles in 
controlling fat and energy metabolism (84,85).  
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Figure 1-3. Phylogenetic tree of selected human GPCR showing protein sequence 
relationship of the human LPA and S1P receptors. The values indicate the lengths of 
the branches. The sequence divergence between any pair of sequences is equal to the sum 
of the value of the branch lengths. A small dot indicates the centroid of the tree. Shorter 
lengths mean more closely related genes. 
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Signal Transduction of LPA Receptors 
The heterotrimeric G proteins serve as important molecular switches that connect 
extracellular signals from GPCRs on the cell membrane to downstream effectors. There are 
four major classes of G protein alpha subunits that are coupled to LPA receptors: Gα
s
, 
Gα
i/o
, Gα
q/11
, and Gα
12/13
. The major signaling routes downstream of G proteins are 
summarized in Fig. 1-4. These include (1) Gi-mediated activation of Ras-mitogen-activated 
protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) - AKT/Rac cascades.  
Activation of Rac and AKT/PKB promotes forward cell movement and cell survival, 
respectively; (2) Gαq-mediated activation of phospholipase C (PLC) and the subsequent 
hydrolysis of phosphatidylinositol-(4,5)-bisphosphate (PIP2) and Ca2+ mobilization from 
ER. (3) Gα12/13-mediated activation of the small GTPase Rho, which promotes contraction 
of the actomyosin-based cytoskeleton leading to changes in cell shape. (4) Gαs-mediated 
adenylate cyclase activation with a subsequent increase in cAMP levels leading to 
activation of cAMP dependent protein kinase A (PKA). It has been shown that LPA1 and 
LPA2 interact with Gi, Gq and G12/13 while LPA3 only interacts with Gi and Gq (1). LPA4-5 
appears to couple to Gs, in addition to Gq and G12/13 (54,55,59,60). By acting on its specific 
GPCR, LPA can exert diverse biological effects including stimulation of cell growth and 
survival, cytoskeleton remodeling, and promotion of cell motility. 
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Figure 1-4. LPA receptors and signal transduction. LPA binding to its cognate 
receptors leads to activation of specific intracellular G proteins and the subsequent 
activation of multiple signaling cascades. The diagram outlines the signaling pathways that 
are linked to the well-characterized biological functions of LPA such as stimulation of cell 
proliferation, survival and motility.  
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LPA and Cell Motility 
Stimulation of cell migration and invasion is one of the major biological functions 
of LPA and its producing enzyme ATX. ATX was originally identified as a tumor cell 
motility-stimulating factor (39). LPA- and ATX-induced cell migration is mediated mainly 
by the LPA1 receptor although LPA2 or LPA3 may be also capable of evoking the response 
in various cellular contexts. 
LPA is involved in regulation of the small Rho GTPases, RhoA, Cdc42 and Rac, all 
of which are crucial modulators of cell motility (86). Specifically, RhoA mediates 
actomyosin-driven contractility and stress fibers formation and Cdc42 controls filopodia 
formation, whereas Rac regulates lamellipodia protrusion and drives forward cell 
movement. LPA activates RhoA via Gα12/13 subunits (87) which bind directly to Rho-
specific guanine nucleotide exchange factors (Rho-GEFs) including p115-RhoGEF, LARG 
and PDZ-Rho-GEF. These exchange factors promote RhoA-GTP accumulation and initiate 
activation of Rho-associated coiled-coil containing protein kinase 1 (ROCK). ROCK 
promotes actin polymerization and inhibits myosin light chain phosphatases (PP1M), 
thereby increasing phosphorylation of myosin light chain (MLC) by MLC kinase and 
actomyosin contraction (88). The actomyosin-based cell contraction underlies neurite 
retraction, cell rounding, and endothelial tight junction opening (13,89,90). On the other 
hand, following initial cell rounding, LPA promotes cell spreading, lamilipodia formation 
and cell movement by activating the Rac GTPase through an LPA1-Gi-mediated pathway 
that involves PI3K activity and the guanine nucleotide exchange factor Tiam1 (91).  
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Cell migration propelled by repeated cycles of protrusion at the leading edge and 
retraction at the trailing end has to be coordinated with cell adhesion to allow directional 
movement. In this respect, although Rac and Rho are signaled through distinct G protein 
pathways, they affect each other’s activity (92). In fibroblasts, activation of Rac has been 
shown to specifically down-regulate Rho activity (93). In keeping with this, fibroblasts 
from Tiam1-deficient mice shows enhanced RhoA activity, stress fiber formation and cell 
rounding in response to LPA (91). This may be explained by Rac-mediated production of 
reactive oxygen species (ROS) leading to activation of p190RhoA-GAP hence reduction of 
RhoA-GTP levels (94). Likewise, excessive Rho also inhibits Rac activation (95). 
Therefore, cell migration is coordinated by relative activities of Rac and Rho. Little is 
known about how the migratory response to LPA is appropriately controlled in mammalian 
cells that usually coexpress multiple LPA receptor subtypes of different abilities to activate 
Rac and Rho. 
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CHAPTER 2: LPA4/p2y9/GPR23 AS A NOVEL RECEPTOR OF LPA 
 
Introduction 
LPA had been a subject of extensive research in signal transduction and physiology 
(2,6,96-99). Although there was strong evidence for the involvement of specific GPCRs in 
biological actions of LPA (100), the search for LPA receptors had been unsuccessful until 
1996 due to lack of specific receptor antagonists, difficulty in ligand-binding experiments 
and the ubiquitous presence of LPA response in most cell types (101). The first LPA 
receptor, LPA1 was cloned and identified from mouse cortical neuroblasts cDNA (5). 
Following the discovery of the first LPA receptor, the other two Edg LPA receptors (LPA2 
and LPA3) were identified based on the sequence similarities to LPA1. Other five members 
of the Edg family are found to be specific receptors for S1P. The Edg LPA receptors 
mediate many physiological functions of LPA. However, there is evidence that additional 
non-Edg LPA receptors might exist. For examples, in embryonic fibroblasts from LPA1 
and LPA2 double knockout mice, certain responses to LPA such as inositol phosphate 
production, adenylyl cyclase inhibition and stress fiber formation were reduced but not 
eliminated. (79). In these cells, LPA3 mRNA was not expressed, suggesting the presence of 
extra LPA receptor(s). In addition, skin fibroblasts from LPA1 and LPA2 double 
knockouts, LPA remained capable of stimulating partial activation of Rho (62).  
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Further evidence stems from targeted deletions of LPA1-3 receptors. Only minor 
phenotypic changes were seen in LPA1 or LPA2 receptor-deficient mice (63,79). 
Homozygous deletion of the LPA3 receptor leads to a delayed implantation and defective 
embryo spacing, associated with reduced uterine expression of COX-2 mRNA (83). While 
these roles for individual receptors have been identified, more profound effects such as 
early embryonic lethality have not been observed from single or even double receptor 
knockouts. These results are in contrast to deletion studies of the LPA synthesizing 
enzyme autotoxin (ATX) where homozygous deletion results in embryonic lethality at 
E9.5 due to impaired vessel formation in the yolk sac and embryo proper (37,38). These 
results suggest involvement of other yet unidentified receptors as effectors of ATX.  
In 2003, the fourth LPA receptor LPA4/p2y9/GPR23 of the purinergic receptor 
(P2Y) family was described by Dr. Shimizu’s group (54). This putative LPA receptor was 
notable for its low amino acid sequence homology with the three well studied Edg LPA 
receptors, and its ability to increase cAMP production by coupling to Gαs subunit (54). 
Furthermore, LPA4 was reported to be highly expressed in the ovary (54). 
Because of the structural difference from the Edg LPA1-3 receptors, there has been 
skepticism about whether LPA4 is a bona fide LPA receptor. Misidentification of receptors 
for LPA and other bioactive lipids has occurred previously (102-106). Therefore, 
independent confirmation of LPA4 identity as a functional LPA receptor is necessary 
before further analysis of its role in LPA signal transduction. In this section of my study, I 
performed a number of assays to establish that LPA4 is indeed a functional LPA receptor. 
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Different from the Edg LPA receptors, however, LPA4 mediates only a subset cellular 
response to LPA.   
 
Materials and Methods 
Reagents  
1-Oleoly (18:1) LPA and [3H]-1-Oleoly (18:1) LPA was obtained from Avanti 
Polar Lipids, Inc. (Alabaster, AL). Prior to use, LPA was dissolved in PBS containing 
0.5% fatty acid-free bovine serum albumin (BSA). BSA and protease inhibitor cocktail 
tablets were purchased from Roche (Indianapolis, IN). Plasmid DNA was purified using 
the endo-free purification kit from Qiagen (Valencia, CA). All oligonucleotides and 
primers were synthesized by Operon Biotechnologies, Inc (Huntsville, AL). TRIzol and 
cell culture medium were obtained from Invitrogen Inc. (Carlsbad, CA). Fetal bovine 
serum (FBS) was from Biomeda (Foster City, CA). Anti-pan tyrosin phosphorylation, anti-
tubulin, anti-Paxillin, and anti- GSK3α/β antibody were obtained from Cell Signaling 
(Danvers, MA). Polybrene and anti β-actin monoclonal antibody were obtained from 
Sigma (St. Louis, MO).  The rabbit polyclonal antibody against the C-terminus of the 
human LPA4 was kindly provided by Dr. T Shimizu (University of Tokyo). Luciferase 
assay reagents were obtained from Promega (Madison, WI).  
 
Cell culture 
The B103 rat neuroblastoma cell line lacking endogenous LPA receptors was 
obtained from Dr. J. Chun (Scripps Research Institute) and cultured in DMEM (Invitrogen) 
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supplemented with 10% FBS, 100 units/ml penicillin and 100 µg/ml streptomycin (107). 
NIH 3T3, Rat hepatoma 7777, and the ecotropic envelope-expression packaging cell line 
Bosc23 cells were obtained from ATCC (Manassas, VA) and cultured as recommended by 
ATCC. All the cell lines were frozen at early passages and used for less than 10 weeks in 
continuous culture. 
 
Construction of Retrovirus Expression Vectors  
The human LPA4 and LPA1 cDNAs were inserted between BamH I and Xho I sites 
upstream of the internal ribosomal entry site of the Moloney murine leukemia retrovirus 
vector LZRS-EGFP (a gift of J. Chun, Scripps Research Institute) (107). The structure and 
the insert sequences were confirmed by restriction digestion and automatic sequencing.  
 
Generation of the LPA4 and LPA1 retrovirus and infection of target cells 
The Bosc23 packaging cells were transfected with LZRS-EGFP, LZRS-EGFP- 
LPA4 or LZRS-EGFP-LPA1 using Lipofectamine 2000 following the protocol of the 
manufacturer (Invitrogen). Approximately 20 hours after the beginning of transfection, the 
cells were fed fresh DMEM supplemented with 10% FBS. Culture supernatants containing 
retrovirus were harvested 48 hours late, cleared by brief spin and used to recipient or stored 
at –80°C. 
The recipient cells in 35-mm dishes at around 50% confluence were incubated for 
16 hours with 1.5 ml of viral supernatants containing 8 μg/ml of Polybrene (Sigma). The 
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positive cells were isolated by FACS and expanded as stable lines expressing LPA4 or 
LPA1. 
 
LPA binding assay  
NIH 3T3 or Rat hepatoma 7777 cells stably transduced with LPA4, LPA1 or control 
retrovirus were starved overnight, and then harvested in binding buffer 25 mM HEPES 
[pH 7.5] containing 20 μM A-PMSF and protease inhibitor cocktail (Roche, Mannheim, 
Germany). The lysates were then sonicated three strokes with 20 sec on and 1 min off at 
level 2. The sonicated samples were first cleared at 1000 × g for 10 min at 4 °C and the 
supernatant was further centrifuged at 10,000 × g for 1 hr at 4 °C. The pallets were 
resuspended with binding buffer and homogenized using a Dounce homogenizer. 
Membrane samples (40 μg) was incubated with 1 μM [
3
H]-LPA (1-oleoyl-[9, 10-
3
H]-LPA, 47 Ci/mmol,) in LPA-binding buffer containing 0.1 % fatty acid-free BSA 
(Sigma) for 1 hr on ice. The bound [
3
H]-LPA was collected onto a GF/B glass fiber filter 
(Whatman, NJ). The filter was then washed four times with PBS on 1225 sampling 
manifold (Millipore, MA) and dried for 1 hr at 65 °C. Radioactivity on the membrane was 
measured in a liquid scintillation counter. To examine the specificity of LPA binding, the 
amounts of LPA bound (using 1 μM of [3H]-LPA) in the presence of excess nonradioactive 
LPA (10 µM) were determined. Total and nonspecific binding was evaluated in the 
absence and presence of 10 µM cold LPA, respectively. The specific binding was 
calculated by subtracting the nonspecific binding value (cpm) from the total reading (cpm). 
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Western Blotting  
Cells were lysed in SDS sample buffer (2% SDS, 62.5 mM Tris [pH 6.8], 10% 
(w/v) glycerol and 5% (w/v) 2-mercaptoethanol). Total cellular proteins were resolved by 
SDS-PAGE, transferred to polyvinylidene difluoride membrane (Immobilon-P), and 
immunoblotted with antibodies following the protocols of the manufacturers. 
Immunocomplexes were visualized with an enhanced chemiluminescence detection kit 
(Amersham Biosciences) using horseradish peroxidase-conjugated secondary antibodies 
(Cell Signaling). 
 
Neurite retraction 
B103 cells were seeded in poly-D-lysine-coated 6-well plates (1.5 × 105/well). 
After 24 hr incubation to allow attachment to the plates, the cells were shifted to serum-
free DMEM for 16 hr. The cells were then treated with 1 μM LPA for 15 min and 
photographed using Zeiss microscope connected to a Canon digital camera. Cells with 
spherical shape lacking neurite longer than cell body and were scored as rounded cells. At 
least three different fields per well were examined with a minimum of 200 cells scored. 
The LPA-induced neurite retraction was expressed as percentages of round cells versus the 
total number of the cells. 
 
Chemotaxis 
Chemotactic migration of cells was measured with transwell chambers made of 
polyethylene terephthalate (BD bioscience, 8 μM pore size). The transwells were coated 
23 
 
with collagen I. LPA was added to the lower chamber, and cells were loaded to the upper 
chamber at 1 × 104 cells/well. After 4 hr, nonmigrated cells on the upper chambers were 
removed by cotton swabs and the cells that traversed and spread on the lower surface of 
the transwell were washed in PBS and stained with 0.1% crystal violet. The migrated cells 
were counted with a microscope and a 20 × objective. Each data point is the average 
number of cells in five random fields, and the number is the average ± SD of triplicates, 
representative of 3 independent experiments. 
 
Statistical analysis of data 
Each data point was calculated from triplicate samples unless otherwise indicated. 
The data presented are mean ± SD. The statistical differences were determined by variance 
or Student’s t test where p<0.05 was considered to be significant. 
 
Results 
Expression of LPA4 mRNA increases with cell density  
LPA4 was reported to be highly expressed in the ovary (54). LPA signaling and 
LPA receptors have been implicated in the development of human malignancies, especially 
ovarian cancers, suggesting the highly expressed LPA4 in the ovary may play a role in 
ovarian carcinogenesis. Therefore we first examined the expression of LPA4 in ovarian 
cancer cell lines and normal ovarian epithelial cells. Consistent with previous observations 
(81), LPA2 and LPA3 are upregulated in ovarian cancer cell lines compared to normal 
ovarian epithelial cells (Fig. 2-1). LPA1 expression was variable showing no consistent 
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changes between normal and cancer cells In contrast to the Edg LPA receptors, LPA4 is 
absent or minimally expressed in ovarian cancer cell lines (Fig. 2-1).   
We examined LPA4 mRNA expression in other cell lines and found that it was 
expressed at significant levels in murine and human fibroblast (Fig. 2-2). Furthermore, 
LPA4 expression in fibroblast was not static. Fig. 2-2 shows Northern blot analysis of LPA4 
mRNA levels in NIH 3T3 cells cultured at approximately 50, 75 and 100% confluence. 
Non-confluent NIH 3T3 cells expressed a relatively low level of LPA4 mRNA. The 
abundance of the transcripts increased when the culture reached higher densities, 
suggesting that LPA4 expression is not constitutive but rather regulated by cell conditions. 
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Figure 2-1. Expression of LPA1-4 receptors in normal ovarian epithelial cells and 
ovarian cancer cell lines. Expression of LPA1-4 receptors in normal ovarian epithelial cells 
(NOE) and six ovarian cancer cell lines was analyzed by RT-PCR. GAPDH was included 
as loading controls.  
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Figure. 2-2. Upregulation of LPA4 mRNA by cell density in NIH 3T3 cells. Total 
cellular RNA was prepared from NIH 3T3 cells of different densities (50, 75 and 100% 
confluence). LPA4 and LPA1 mRNA levels were examined by Northern blotting analysis 
with 32P-labeled LPA4 or LPA1 cDNA as probes. The blot was reprobed with GAPDH and 
18S to confirm equal loading among samples.  
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LPA binds to LPA4 
To determine whether LPA4 indeed physically binds to LPA, we performed LPA 
binding assay with membrane fractions isolated from NIH 3T3 cells overexpressing LPA4 
or LPA1. To overexpress LPA4 or LPA1 in NIH 3T3 cells, high titers of retrovirus 
produced in the Bosc23 packaging cell line was used to infect NIH 3T3 cells. The stably-
transduced cells were isolated by fluorescence-activated cell sorting (FACS). Northern 
blotting analysis confirmed mRNA expression of LPA4 or LPA1 in the transduced cells 
(Fig. 2-3B)  
Membrane fractions were prepared from control NIH 3T3 and LPA1- or LPA4-
transduced NIH 3T3 cells and incubated with 1μM [3H]-LPA in the presence or absence of 
10 μM cold LPA. The specific binding between LPA and the membrane preparations was 
determined by extensive washing. Both LPA1 and LPA4-transduced membranes showed 
significantly increased binding to [3H]-LPA compared to membranes isolated from control 
cells (Fig. 2-3B). To further confirm the physical binding of LPA4 to LPA, we performed 
the binding assay, in Rh7777 which lack endogenous LPA receptors.  LPA1 or LPA4 was 
transduced into Rh7777 cells via retrovirus-mediated transduction. When cultured in 
complete medium, the control Rh7777 cells showed a rounded, refractile appearance. In 
contrast, Rh7777-LPA1 cells displayed a more flattened morphology. The cells expressing 
LPA4 show morphological appearances between control Rh7777 and LPA1-expressing 
cells, suggesting the exogenous expressed LPA1 and LPA4 are functional in Rh7777 cells 
(Fig. 2-4). As expected, control Rh7777 cells lacking endogenous LPA receptors showed a 
low background binding to [3H]-LPA. Expression of either LPA1 or LPA4 greatly enhanced 
28 
 
[3H]-LPA binding to membranes of retrovirus transduced Rh7777 cells (Fig. 2-5). These 
observations indicated that similar to the well characterized LPA1 receptor, LPA4 was 
indeed capable of binding to LPA.   
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(A)  
 
(B) 
 
Figure 2-3. [3H]-LPA binding to plasma membranes of NIH 3T3 cells expressing 
LPA4. (A) RNAs (25 μg) from NIH 3T3 stably infected with control, LPA1 or LPA4 
retrovirus were subjected to Northern blot analysis. 18S RNA served as loading control. 
(B) [3H]-LPA non-specific and specific binding in plasma membranes of NIH 3T3 cells 
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expressing control vector, LPA1 or LPA4. Data are the mean ± SD (n =3). *, p = 0.0056; 
**, p = 0.0062 (Student’s t test) versus empty vector expressing cells.  
  
 
                      Rh7777‐vector                 Rh7777‐LPA1                    Rh7777‐LPA4 
     
 
Figure 2-4. Microscopic morphology of control, LPA1 or LPA4-transduced Rh7777 
cells. Phase-contrast microscopic photographs of Rat hepatoma 7777 cells stably 
transduced with vector control, LPA1, or LPA4 retrovirus.  
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Figure 2-5. Physical binding of [3H]-LPA to LPA1 or LPA4 ectopically expressed in 
Rh7777 cells. Membrane fractions (40 μg) from vector-, LPA1- or LPA4-transduced 
Rh7777 cells were incubated with [3H]-LPA for 1 hour. Specific binding was assessed in 
the presence of 10 μM LPA. Data are presented as means ± SD (n =3). Asterisks indicate 
significant differences from the control. *, p = 0.0045; **, p = 0.0031 (Student’s t test) 
versus empty vector expressing cells. 
 
 
 
 
 
32 
 
LPA4 mediates LPA-induced protein tyrosine phosphorylation in Rh7777 cells  
LPA stimulates protein tyrosine phosphorylation in fibroblasts and epithelial cells 
(108-111). To determine whether LPA4 was capable of mediating tyrosine phosphorylation 
of intracellular proteins, we assessed LPA-induced tyrosine phosphorylation in Rh7777 
cells transduced with control, LPA1 or LPA4 retrovirus. Western blot analysis with anti-
pan phosphotyrosine antibody (Cell Signaling) was performed to detect tyrosine-
phosphorylated proteins induced by treatment with different concentrations of LPA for 5 
min. As shown in Fig. 2-6A, LPA induced tyrosine phosphorylation of a group of proteins 
of molecular weight 60-70 kD in LPA1 and LPA4 expressing cells, but not in control virus 
transduced cells. The stimulation of tyrosine phosphorylation by LPA was dose dependent 
with the maximal effect seen at 1μM.  Since LPA induced tyrosine phosphorylation of 
various isoforms of paxillin with similar molecular weights (111), we examined whether 
the tyrosine phosphorylated proteins represent paxillin by immunoblotting with a paxillin 
phospho-specific antibody. As shown in Fig. 2-6B, LPA stimulated strong tyrosine 
phosphorylation of paxillin in LPA1 expressing cells, but not in LPA4 or control cells, 
indicating that the tyrosine phosphorylated proteins seen in LPA4-expressing cells were not 
paxillin. Further, LPA1, but not LPA4 was capable of mediating LPA-induced paxillin 
phosphorylation. 
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(A) 
  
(B) 
                                               
Figure 2-6. LPA4 mediates LPA-dependent tyrosine phosphorylation in Rh7777 cells. 
(A) LPA induced tyrosine phosphorylation of 60-70 kD proteins in LPA1 or LPA4-
expressing Rh7777 cells but not in vector control cells. The cells were stimulated for 5 min 
with the indicated concentrations of LPA, and analyzed by immunoblotting with an anti- 
phosphotyrosine antibody. (B) LPA1, but not LPA4 mediated LPA-induced paxillin 
phosphorylation. Control, LPA1, or LPA4-expressing Rh7777 cells were stimulated with 
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1μM LPA for the indicated periods of time (min). The cell lysates were analyzed by 
immunoblotting using anti-phospho paxillin antibody or anti-GSK3α/β antibody (loading 
control). 
 
LPA4 does not mediate activation of MAPK or AKT in Rh7777 cells 
 To obtain further evidence that LPA4 impinges on LPA signal transduction, we 
examined whether LPA4 mediates the activation of ERK and AKT as do the Edg LPA 
receptors. In Rh7777-LPA1 expressing cells, LPA induced a dose-dependent 
phosphorylation of ERK and AKT. However, LPA at concentrations up to 10 μM did not 
induce AKT and ERK phosphorylation in control or LPA4-expressing cells. Since AKT 
and ERK activation by LPA is Gi dependent, the data is consistent with the inability of 
LPA4 to couple to Gi (54,59,60). 
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Figure 2-7. LPA1, but not LPA4 mediates LPA-induced ERK and AKT 
phosphorylation in Rh7777 cells. The vector, LPA4, or LPA1-expressing Rh7777 cells 
were grown to subconfluence, starved in serum-free medium and stimulated with LPA at 
indicated concentration for 5 mins. The cells were lysed and analyzed for AKT and ERK 
phosphorylation by immunoblotting. The total ERK was included as protein level controls.  
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LPA4 mediates neurite retraction, but does not evoke migratory response to LPA in the 
B103 neuroblastoma cells  
LPA induces cytoskeleton remodeling and morphological changes. In neuronal 
cells, LPA triggers neurite retraction and cell rounding. This response is mediated via 
activation of Rho by LPA receptors (5,90). Since LPA4 couples to the G12/13-Rho pathway, 
we examined the ability of LPA4 in stimulation of neurite retraction and cell rounding in 
rat neuroblastoma B103 cells which do not have significant expression of endogenous LPA 
receptors (107). The parent cell line did not respond to LPA stimulation (60). Therefore, 
we overexpressed LPA4 or LPA1 in B103 cells by retrovirus mediated transduction as 
described above. The exogenous expression of LPA4 or LPA1 in transduced cells was 
confirmed by western blot (Fig. 2-8A). The predicted molecular mass for LPA4 nd LPA1 
are both around 40-50 kDa. However, Western blotting analysis showed the presence of 
multiple bands specifically recognized by anti-LPA4 antibody in LPA4-tranduced cells, 
likely representing formation of aggregates and/or post-translational glycosylation of the 
overexpressed LPA4.  
The LPA receptor-transduced cells displayed morphologies different from each 
other or from control virus-infected cells (Fig. 2-8B). B103-LPA4 cells had tendency to 
form aggregates particularly at relatively low cell density while expression of LPA1 was 
associated with a more flattened cell shape as described previously (60,91). After 
incubation overnight in serum-free medium, the majority of the cells showed long neurites. 
Upon LPA stimulation, neurites remained to be extended in the parent or B103-vector cells 
upon LPA stimulation. In sharp contrast, LPA induced rapid and robust retraction of 
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neurites in LPA1- or LPA4- expressing B103 cells (Fig. 2-9). Most cells became rounded 
and lost neurites within minutes of LPA stimulation. As indicated in Fig. 2-9, 20-30% cells 
were scored round compared to less than 5% control cells showing round morphology. The 
data suggests that expression of LPA4 is sufficient to induce neurite retraction in response 
to LPA.   
We next examined whether LPA4 mediates LPA-induced chemotactic migration 
using transwell chambers precoated with collagen. As shown in Fig. 2-10, LPA strongly 
stimulated migration of B103-LPA1 cells but not of B103-vector or B103-LPA4 cells. The 
data suggest that LPA4 is not competent to evoke the migratory response to LPA although 
it was highly expressed in the transduced B103 cells. 
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(A) 
      
(B) 
                  B103­vector                            B103­LPA1                               B103­LPA4  
     
 
Figure 2-8. Overexpression of LPA1 or LPA4 in B103 cells leads to morphological 
changes. (A) B103 cells were infected with vector, LPA1 or LPA4-expressing retrovirus. 
The expression of LPA1 and LPA4 was confirmed by Western blotting. (B) Phase-contrast 
microscopic photographs of vector control, LPA1 and LPA4- expressing B103 cells.  
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(A)                                                                         (B)      
    
 
                            
 
Figure 2-9. LPA4 mediates neurite retraction in LPA-treated B103 cells. Serum-
starved B103 cells (vector, LPA1- or LPA4-expressing) were exposed to 1 μM LPA for 15 
min. LPA-induced neurite retraction was monitored under microscope (A) and quantified 
as percentages of round cells versus total number of cells (B). Data are the mean ± SEM (n 
= 3). *, p = 0.00028; **, p = 0.000017 (Student’s t test). 
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Figure 2-10. LPA4 does not mediate LPA-induced chemotaxis. LPA-induced 
chemotactic migration of vector, LPA1 or LPA4-expressing B103 cells was analyzed with 
transwell chambers as detailed in Materials and Methods. The cells (1 × 104 cells/well) 
were loaded onto the wells and allowed to migrate toward 1μM LPA for 4 hr. The data are 
expressed as the average number of cells in five randomly selected fields under microscope 
(200 ×) ± SD of triplicate determinations, representative of three independent experiments. 
*, p = 0.00035 (Student’s t test). 
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Discussion 
A major advance in understanding roles of lysophospholipids has been the 
identification of LPA receptors that meet clear, unambiguous criteria for receptor function, 
combined with independent confirmation of the proposed identity. In the lysophospholipid 
receptor field, multiple instances of misidentification have occurred, most notably the 
following: OGR1 as a sphingosylphosphorylcholine receptor (102), GPR4 as a 
lysophosphatidylcholine and sphingosylphosphorylcholine receptor (106), G2A as an 
lysophosphatidylcholine receptor (104,116), and mammalian PSP24 s as an LPA receptor 
(105). Since the initial report of LPA4 as a novel LPA receptor in 2003, it has been 
controversial whether this is indeed a functional LPA receptor mainly due to its different 
structure from the known Edg LPA receptors. 
My assessment here of LPA4 supports its initial identification (54). Several lines of 
evidence include induction of protein tyrosine phosphorylation and neurite retraction/cell 
rounding. These cellular responses to LPA are known to be mediated through the G12/13-
Rho signaling cascade, indicating that LPA4 is an LPA receptor subtype coupled to the 
G12/13 subunit effectively. The most definitive evidence for the identity of LPA4 was 
provided by the specific binding of [3H]-LPA to heterologously expressed LPA4 present in 
membrane fractions. Due to the hydrophobic nature of the lysophospholipids resulting in 
heavy nonspecific background binding to cell membrane, the receptor-ligand binding 
analysis is not a straight-forward assay. We have used both LPA receptor-positive and 
negative cell lines to assess the binding between LPA and cell membrane fractions. In both 
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cell types, we were able to show increased membrane binding to LPA in the cells 
overexpressing exogenous LPA4 compared to the cells not overexpressing LPA4.  
Compared to the pluropotent LPA1 receptor, LPA4 was not capable of mediating 
LPA-induced activation of ERK and AKT which are located downstream of Gi protein. 
The data confirms that LPA4 does not couple to Gi subunits of trimetric G proteins. 
Consistent with this, LPA4 does not mediate migratory response to LPA, a biological 
action of LPA dependent on Gi-mediated signaling processes. In summary, our results 
indicate that LPA4 is a functional LPA receptor. Different from the LPA1 receptor, LPA4 
mediates only a subset of cellular responses to LPA.  
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CHAPTER 3: GENERATION OF LPA4/p2y9/GPR23-DEFICIENT 
MICE 
Introduction 
LPA4, LPA5 and LPA6 of the purinergic receptor family are structurally distant 
from the Edg LPA1-3 receptors. The structure difference implies that LPA4 LPA5, or LPA6 
may possess physiological functions different from those of the Edg LPA receptors. 
However, little is known about the expression and functions of these newly identified LPA 
receptors. Targeted deletion is one of the most relevant models to examine the biological 
roles of genes of interest. It has become an important approach to probe functions of the 
Edg LPA1-3 receptors in embryonic development, health and diseases. Although initial 
analysis revealed only minor phenotypic changes associated with loss of individual LPA 
receptors, more extensive studies of these animals have elucidated unexpected roles for 
LPA1 in the development of vascular and nervous systems (63), initiation of neuropathic 
pain (66), and promotion of pulmonary and renal fibrosis (64,65). Thus it is critically 
important to develop a knockout mouse model to investigate in vivo functions of LPA4 and 
other new LPA receptors.  
In this part of the study, we disrupted the LPA4-encoding gene (lpa4/p2y9/gpr23) 
by targeted deletion in mice. Similar to knockout of lpa1 or lpa2 (63,79), LPA4-deficient 
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mice did not show obvious abnormalities in embryonic development, fertility or normal 
physiology. However, the availability of the mice and LPA4-null tissues and cells has 
allowed us to analyze phenotypic alterations in cell signaling and responses to LPA, which 
will be discussed in detail in Chapter 3.  
 
Materials and Methods  
Generation of lpa4 targeting vector   
The genomic sequences of the mouse lpa4 (C57BL/6) were isolated and PCR 
amplified from a BAC clone (RP23-343P30) (BACPAC Resources, Oakland, CA). A 
1.965-kb KpnI/EcoRI fragment containing the 3’ part of exon 3 was PCR amplified from 
the BAC DNA and cloned as the short arm into the pKO Scrambler NTKV-1901 targeting 
vector that carries both PGK/neo/BGH cassette for positive selection of homologous 
recombinants with G418 and an MC1-tk cassette for negative selection of non-homologous 
recombinants with gangcyclovir (Stratagene, La Jolla, CA). The 5.34-kb EcoRI/BstBI 
fragment containing exon 2 and the major part of intron 2 was cloned into pBluescript II 
SK (+) from the BAC DNA and recloned using the Not I and Sal I sites into the targeting 
vector. Thus, a 2.591-kb fragment containing the 3’ end of intron 2 and the 5’ portion (with 
the complete coding sequence) of exon 3 was replaced with 1.603 kb of the PGK/neo/BGH 
cassette, creating the final targeting vector (Fig. 3-2A).  
 
Generation of LPA4-deficinet mice  
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All procedures for animal studies were conducted in compliance with the policies 
and regulations of Virginia Commonwealth University IACUC. The lpa4 targeting vector 
was linearized with Not I and electroporated into the 129/Sv embryonic stem (ES) cells 
HZ2.2 (generated by the VCU Transgenic/Knockout Mouse Core). Genomic DNA from 82 
ES cell clones resistant to both G418 and gangcyclovir were screened for homologous 
recombination by long-range PCR using an lpa4 intron 1 sense primer (2717-2740: 5’-
CCAAATGTAGGTGCCACTTGTATG-3’) and a PGK anti-sense primer (5'-
GGTGGATGTGGAATGTGTGCGAG-3') for the long arm, and a neo sense primer (5’-
TCGCCTTCTTGACGAGTTCTTCTG-3’) and a 3’ flanking anti-sense primer (12725-
12702: 5’-GCCTACAGCCTTATGTATTCCAAC-3’) for the short arm. Southern blot 
analysis was performed on DNA from these clones using a PGK/neo/BGH probe to verify 
clone purity and the integrity of both genomic arms. Two independent recombinant clones 
were injected into C57BL/6 blastocysts which were then implanted into pseudopregnant 
CD-1 recipients, producing two independent lines of chimeric male mice. They were bred 
with C57BL/6 females to generate heterozygous female founder mice (X+X-) and wild type 
WT males (X+Y), which were intercrossed to generate more heterozygous females (X+X-) 
and hemizygous KO males (X-Y). These WT, heterozygous and hemizygous mice were 
further crossed to produce all genotypes summarized in Table 1.  
 
Genotyping of lpa4 KO mice 
Genotyping for lpa4 alleles were done by PCR amplification of mouse tail genomic 
DNA. Mouse tail biopsies (0.5 cm) were dissolved in DirectPCR Lysis Reagent (VIAGEN 
46 
 
Biotech, CA) containing 0.2 mg/ml proteinase K at 65°C overnight. The crude lysates were 
incubated in 100°C heat block for 5 min to inactivate residual proteinase K. Mouse hairs 
and undigested tissues were precipitated by brief centrifugation. The supernatants 
containing mouse genomic DNA were used as templates for PCR amplification of genomic 
DNA (40 cycles of 94°C for 1 min, 60°C for 1 min, and 72°C for 2 min) using a common 
lpa4 intron 2 sense primer (7713-7735: 5'-CTATTGCTTTCCCCCATGTTATG-3'), an lpa4 
intron 2 anti-sense primer (8107-8084: 5'-TTACTATTGGCTAGTCTGTCTTTC-3’) for 
the WT allele, and a PGK anti-sense primer (5'-GGTGGATGTGGAATGTGTGCGAG-3') 
for the KO allele (Fig. 3-2C). Expected sizes of the PCR products for WT and KO alleles 
were 395 and 564 bp, respectively. The line was subsequently maintained in a mixed 
129/Sv and C57BL/6 background. 
 
RT-PCR analysis of LPA4 mRNA  
Total RNA was isolated from mouse tissues using TriZol according to the manual 
instruction (Invitrogen). RNA (1 μg) was transcribed to cDNA usingthe ThermoScript™ 
RT-PCR kit (Invitrogen) with random hexamer primers. LPA4 cDNA was amplified by 
PCR using primers: forward 5'- GTGCGAGTTGCCAGTTTACACGTT-3’ and reverse 5'- 
ACTGATGCAGGTGAGGAAGAGCAT-3’. The primers for amplification of LPA1 and 
LPA2 are LPA1 forward primer: 5'-ACTGACTGTTAACACGTGGCTCCT-3’ and reverse 
primer 5'-GGCAGCACACATCCAGCAATAACA-3’; LPA2 forward primer 5’-
ACTGCCTCTGTGACTTGGACAGTT and reverse primer 5’- 
AAGCTGAGTAACGGGCAGACTTGT. GAPDH was used as control. Reaction 
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conditions were optimized to obtain amplification within the logarithmic phase of the 
reaction.  
 
Results 
Development of LPA4-deficient mice 
Similar to the human lpa4, the murine lpa4 gene are located on the X chromosome 
(chrX: 98, 325, 012-98, 336, 788) (Gene ID: 78134). Unlike its intronless human homolog, 
the mouse lpa4 has 3 exons spanning approximately 11.8 Kb while the coding sequence is 
located within exon 3 only. The coding sequence contains an open reading frame of 1113 
base pairs encoding a protein of 370 amino acid residues with a deduced molecular weight 
of 41.89 kDa. To disrupt the lpa4 locus, we replaced the 3’ end of intron 2 and 5’ portion 
of exon 3 that contains the full coding sequences of LPA4 with the PGK/neo/BGH cassette. 
As detailed in Materials and Methods, the chimeric male mice were bred with C57BL/6 
females to generate heterozygous female founder mice (X+X-) and WT males (X+Y), which 
were further intercrossed to generate hemizygous males (X-Y). The genotypes of the 
offspring on the mixed C57BL/6 and 129/Sv background were identified by PCR 
amplification of genomic DNA obtained from tails of mice.  
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(A) 
 
 
(B) 
   1 ATGGGTGACAGAAGATTTATTGACTTCCAATTCCAAGATTTAAATTCAAGTCTCAGACCC 60 
      M  G  D  R  R  F  I  D  F  Q  F  Q  D  L  N  S  S  L  R  P  
 
  61 AGGTTGGGAAATGCAACTGCCAATAATACTTGCATTGTTGATGATTCCTTCAAGTATAAT 120 
      R  L  G  N  A  T  A  N  N  T  C  I  V  D  D  S  F  K  Y  N  
 
 121 TTGAATGGTGCTGTCTATAGTGTTGTATTCATCCTGGGTCTAATAACCAGCAGTGCCTCC 180 
      L  N  G  A  V  Y  S  V  V  F  I  L  G  L  I  T  S  S  A  S  
     TMD I  
 181 CTGTTTGTCTTCTGCTTCCGCATGAAAATGAGAAGTGAGACGGCTATTTTCATCACCAAC 240 
      L  F  V  F  C  F  R  M  K  M  R  S  E  T  A  I  F  I  T  N  
 
 241 CTGGCCCTCTCTGATTTGCTTTTTGTTTGTACCCTACCTTTCAAAATATTTTACAACTTT 300 
      L  A  L  S  D  L  L  F  V  C  T  L  P  F  K  I  F  Y  N  F  
 TMD II 
 301 AATCGCCACTGGCCTTTTGGTGACACCCTCTGTAAGATCTCAGGGACTGCGTTCCTCACC 360 
      N  R  H  W  P  F  G  D  T  L  C  K  I  S  G  T  A  F  L  T  
 
 361 AACATCTATGGGAGCATGCTCTTCCTCACCTGCATCAGTGTGGATCGTTTCCTAGCCATT 420 
      N  I  Y  G  S  M  L  F  L  T  C  I  S  V  D  R  F  L  A  I  
  TMD III 
 421 GTCTATCCCTTCCGATCGCGTACCATCAGGACCAGGAGGAATTCCGCCATTGTGTGCGCT 480 
      V  Y  P  F  R  S  R  T  I  R  T  R  R  N  S  A  I  V  C  A  
 481 GGAGTCTGGATCCTAGTCCTCAGTGGTGGTATTTCAGCTTCTTTGTTCTCCACCACTAAT 540 
      G  V  W  I  L  V  L  S  G  G  I  S  A  S  L  F  S  T  T  N  
  TMD IV 
 541 GTCAACAATGCGACCACCACTTGCTTTGAAGGCTTCTCCAAACGTGTCTGGAAGACATAC 600 
      V  N  N  A  T  T  T  C  F  E  G  F  S  K  R  V  W  K  T  Y  
 
 601 CTGTCCAAGATCACTATATTCATTGAAGTTGTTGGATTCATCATTCCTCTGATATTGAAT 660 
      L  S  K  I  T  I  F  I  E  V  V  G  F  I  I  P  L  I  L  N  
     TMD V 
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 661 GTTTCTTGTTCTTCTGTGGTGCTTAGAACCCTCCGCAAGCCTGCAACATTGTCTCAGATT 720 
      V  S  C  S  S  V  V  L  R  T  L  R  K  P  A  T  L  S  Q  I  
 
 721 GGGACCAATAAAAAAAAAGTGTTGAAGATGATCACAGTGCATATGGCAGTGTTTGTGGTA 780 
      G  T  N  K  K  K  V  L  K  M  I  T  V  H  M  A  V  F  V  V  
 
 781 TGCTTTGTACCATACAACTCCGTTCTCTTTTTATATGCCTTGGTACGCTCCCAAGCCATT 840 
      C  F  V  P  Y  N  S  V  L  F  L  Y  A  L  V  R  S  Q  A  I  
 TMD VI 
 841 ACTAATTGCTTATTGGAAAGGTTTGCAAAGATCATGTACCCAATTACCTTGTGCCTTGCA 900 
      T  N  C  L  L  E  R  F  A  K  I  M  Y  P  I  T  L  C  L  A  
         TMD VII 
 901 ACTCTGAATTGTTGCTTTGATCCTTTTATCTATTACTTCACTCTTGAATCCTTTCAGAAG 960 
      T  L  N  C  C  F  D  P  F  I  Y  Y  F  T  L  E  S  F  Q  K  
 
 961 TCCTTTTATATCAATACACATATAAGGATGGAGTCGCTGTTTAAGACTGAGACACCTCTG 1020 
      S  F  Y  I  N  T  H  I  R  M  E  S  L  F  K  T  E  T  P  L  
 
1021 ACCCCCAAACCTTCCCTTCCAGCTATCCAAGAGGAAGTTAGTGATCAAACAACAAATAAT 1080 
      T  P  K  P  S  L  P  A  I  Q  E  E  V  S  D  Q  T  T  N  N  
 
1081 GGTGGTGAATTAATGCTGGAATCCACCTTCTAG 1113 
      G  G  E  L  M  L  E  S  T  F  *  
 
Figure 3-1. Diagrammatic representation of the genomic structure of mouse lpa4 gene 
and coding sequences with its putative seven transmembrane domains. (A) Schematic 
representation of the domain structures of the mouse lpa4 gene. (B) Coding sequences and 
corresponding amino acids. 
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(B) 
                      
 
 
(C) 
                          
 
 
Figure 3-2. Generation of LPA4-deficient mice. (A) Schematic representations of the 
wild type lpa4 allele, targeting vector, and the targeted allele are shown. The positions of 
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neo and tk genes, restriction sites and exon 2 and 3 are indicated. The targeting vector pKO 
Scrambler NTKV-1901 containing the neo gene was used to replace the 3’ portion of 
intron 2 and the 5’ fragment of exon 3 which carries the entire coding sequence of LPA4. 
The positions of primers for long chain PCR of long arm and short arm detection are 
indicated by the arrowheads. (B) Genomic DNA prepared from two independent ES cell 
clones was subjected to Southern blot analysis after digestion with Bam HI or Alw NI 
restriction enzymes. A DNA fragment generated from sequence within PGK/neo gene was 
used as probe. Bands corresponding to the lpa4 null allele with each digestion are 
indicated. (C) Genotyping by PCR amplification of genomic DNA obtained from mouse 
tails confirmed the DNA arrangements consistent with X+Y, X-Y, X+X+, X+X-, and X-X- 
genotypes. The relative locations of 3 primers used for PCR detection of wild type and KO 
alleles are indicated by the arrowheads. The product size of 395 bp and 564 bp represent 
the wild type and KO alleles, respectively.  
 
 
 
 
 
 
 
Characterization of lpa4 heterozygous and homozygous mice  
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As demonstrated in Table 1, the gender ratios of the offspring 
[male/(male+female)] from X+Y × X+X- crossing and from X-Y × X+X- crossing were 43.5 
% and 46.6 %, respectively with an overall percentage of 45.1 %, slightly lower than the 
expected 50%. The differences, however, lacked statistical significance when examined 
with the chi-square test of goodness-of-fit. In addition, heterozygous females (X+X-), 
homozygous females (X-X-) and hemizygous males (X-Y) were born at statistically expected 
Mendelian rule, reflecting that loss of LPA4 does not cause embryonic lethality or impose a 
detrimental effect on embryonic development (Table 1). The lpa4 KO mice were grossly 
indistinguishable from their WT or heterozygous littermates in appearance, size, and 
behavior (Fig. 3-3). They did not show any defects in mating, pregnancy, or litter sizes. 
There were no gross abnormalities in the internal organs of LPA4-deficient adults (data not 
shown). Some LPA4-deficient mice have survived 18 months, indicating that the loss of 
LPA4 does not shorten life span of mice. 
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   WT            KO        WT    KO 
Figure 3-3. Pictures of lpa4 WT and KO mice.  
 
 
 
 
 
 
 
 
Table 1. Inheritance of the lpa4 deletion allele 
 
                                     No. of offspring with lpa4 genotypes                                             
 
                                             males                  females                        
 
Crossing pairs                 X+Y     X-Y         X+X+    X+X-     X-X-           Sex ratio          Total No. of mice  
                                                                                                            m:f (% m/m+f)                                                                      
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 X+Y × X+X-             24       36             40        38          0             60:78  (43.5)             138 
                                     (17.4)  (26.1)       (29.0)   (27.5)     (0) 
 
X-Y × X+X-              33       29              0          41         30             62:71 (46.6)              133 
                                    (24.8)  (21.8)         (0)     (30.8)     (22.6)   
 
Numbers of individual progeny genotyped from the indicated crosses are shown. In 
parentheses are the percentages of the mice with the indicated genotypes or percentages of 
males versus the total numbers of mice generated from the indicated crosses. 
 
 
 
 
 
 
 
 
 
 
 
Expression of LPA4 in mice tissues  
To delineate the tissue distribution of LPA4, we examined its mRNA expression in 
a number of adult tissues including the liver, heart, skeleton muscle, rectum, kidney, lung 
and ovary, uterus or testis. As analyzed by RT-PCR, LPA4 mRNA transcript was present in 
56 
 
the heart, skeleton muscle and ovary but weakly seen in the liver or testis (Fig. 3-4A). 
Further analysis of more tissues of adult mice indicates that LPA4 mRNA was present in 
the lung, kidney, and rectum (Fig. 3-4B). The expression of LPA4 mRNA in these tissues 
was absent from homozygous females and hemizygous males further confirming loss of 
LPA4 in lpa4 KO mice. The expression of LPA1 transcripts in the these tissues among wild 
type, heterozygous, and knockout mice was not significantly changed, suggesting that loss 
of LPA4 does not lead to compensatory increases in expression of other LPA receptors.  
 
 
 
 
 
 
 
 
 
 
 
(A) 
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(B) 
 
 
Figure 3-4. Homozygous deletion of lpa4 in KO mice and the expression patterns of 
LPA4 in adult mice tissues. RNA was extracted from adult mouse tissues and reverse 
transcription-PCR was performed with 27 cycles (A) or 35 cycles (B) amplification. The 
products were separated on agarose gels and visualized with ethidium bromide staining. 
RT-PCR amplification of GAPDH or LPA1 was included as controls.  
 
 
Discussion 
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To understand the physiological functions of the LPA4 receptor, we have disrupted 
its encoding gene in mice by targeted deletion. The lpa4 KO mice were born at expected 
Mendelian frequency without sexual bias. The adult mice were physiologically normal and 
were grossly indistinguishable from their WT siblings in appearance, size, and behavior, 
suggesting that LPA4 is not required for embryonic development and normal physiology. 
This is similar to targeted deletion of lpa1 or lpa2 (63,79). One plausible explanation for the 
lack of prominent phenotypes in LPA4-deficient mice is that other backup and/or 
redundant receptor subtypes of LPA may suffice to compensate for the loss of these LPA 
receptors in vivo. In particular, the recently identified LPA5 and LPA6 receptors are closely 
related to LPA4. Alternatively, LPA, as one of phospholipids present in the circulation and 
tissues, may not be only or rate-limiting mediator physiologically required in vivo. LPA 
signaling may be more critical in pathophysiological settings when levels of the lipid 
mediator are locally and temporally altered. In light of the pathophysiological significance 
of LPA signaling, it will be interesting to study the LPA4-deficient mice in stress such as 
tissue injury, inflammation or exposure to chemical carcinogens, which may reveal novel 
functions of the receptor. Recent studies of LPA1-deficeint mice subjected to injury 
demonstrated the involvement of LPA1 in abnormal wound healing and fibrosis formation 
(64-66), consistent with a major role of this LPA receptor in chemotactic recruitment of 
fibroblasts to the site of wound.  
The availability of the lpa4 KO mice makes it possible to generate mice lacking 
multiple isoforms of LPA receptors to address the redundancy and complexity of LPA 
signaling. Furthermore, LPA4-deficient mice provide us a unique opportunity to study the 
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functional consequence of loss of LPA4 by using truly LPA4–negative tissues and cells. 
We have obtained such results that suggest a role of LPA4 in antagonism of the Edg LPA 
receptors as will be discussed in Chapter 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
 
CHAPTER 4: LPA4/p2y9/GPR23 IN NEGATIVE REGULATION OF 
CELL MOTILITY 
Introduction 
Stimulation of cell motility is one of the major biological effects of LPA and its 
producing enzyme ATX. LPA-induced cell movement is mediated mainly by LPA1, 
although LPA2 or LPA3 may also capable of evoking the response to a lesser degree in 
various cellular contexts (3,11,36,62,117,118). However, little is known about how the 
migratory response to LPA is appropriately controlled in mammalian cells that usually 
coexpress multiple LPA receptor subtypes endogenously. The lpa4 KO mice we have 
developed provide a valued cellular model to analyze the migratory response to LPA in the 
absence of a specific receptor. The results of the experiments using LPA4-deficient cells 
and other cellular models establish a novel role of LPA4 in the negative control of LPA-
mediated cell migration and invasion. We demonstrated that LPA4-deficient mouse 
embryonic fibroblasts (MEFs) from lpa4 KO mice were hypersensitive to LPA-induced 
migration. Consistent with negative modulation of the phosphatidylinositol 3 kinase 
pathway by LPA4, LPA4 deficiency potentiated AKT and Rac but decreased Rho activation 
induced by LPA. Reconstitution of LPA4 converted LPA4-negative cells into a less motile 
phenotype. In support of the biological relevance of these observations, ectopic expression 
of LPA4 strongly inhibited migration and invasion of human cancer cells. When 
coexpressed with LPA1 in B103 neuroblastoma cells devoid of endogenous LPA receptors, 
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LPA4 attenuated LPA1-driven migration and invasion, indicating functional antagonism 
between the two subtypes of LPA receptors. These results provide genetic and biochemical 
evidence that LPA4 is a suppressor of LPA-dependent cell migration and invasion in 
contrast to the motility-stimulating Edg LPA receptors. 
 
Materials and Methods 
Reagents  
Protease inhibitor cocktail tablets and BSA were purchased from Roche 
(Indianapolis, IN). Plasmid DNA was purified using the endo-free purification kit from 
Qiagen (Valencia, CA). All oligonucleotides were synthesized by Operon Biotechnologies, 
Inc (Huntsville, AL). TRIzol and cell culture medium were obtained from Invitrogen Inc. 
(Carlsbad, CA). Fetal bovine serum (FBS) was from Biomeda (Foster City, CA). 
Epidermal growth factor (EGF), Ki16425, and anti-flag M2 and anti-ß-actin monoclonal 
antibodies were obtained from Sigma (St. Louis, MO). Pertussis toxin (PTX) was 
purchased from List Biological Laboratories, Inc. (Campbell, CA). AKT inhibitor II (AKTi 
II) was obtained from Calbiochem (San Diego, CA). Anti-phospho AKT, anti-phospho 
ERK and anti-tubulin antibodies, and LY294002 were obtained from Cell Signaling 
(Beverly, MA). The rabbit polyclonal antibody against the C-terminus of the human LPA4 
was kindly provided by Dr. T Shimizu (University of Tokyo). 
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MEFs   
MEFs were isolated from E12.5–13.5 embryos essentially as described (120).  The 
embryos were separated from the uterine wall and amniotic sac and placed in Petri dishes 
containing small volumes of PBS. The head and heart tissues were removed. The 
remaining embryo were minced with surgical scissors and razor blade, digested with 
0.25% trypsin/EDTA at 37 oC for 25 min, and triturated through a Pasteur pipette. After 
digestion and removal of undigested tissues, the cells were spun briefly and plated into a 
10-cm dish and allowed to grow to subconfluence in DMEM+10% FBS. The cells were 
then either frozen as passage 1 or subcultured at a 1:4 ratio for experiments. Immortalized 
cell lines were established from primary MEFs using standard protocols for generation of 
3T3 cells (121). 
The genotypes of MEFs were determined by PCR amplification of genomic DNA 
isolated from MEFs as described in Chapter 3. The gender of embryos was determined by 
PCR amplification of the SRY (Sex-determining Region Y gene) locus with a SRY-sense 
primer (5'-ATTTATGGTGTGGTCCCGTGGTGA-3') and a SRY anti-sense primer (5'-
TTGCCTGTATGTGATGGCATGTGG -3'). The size of the PCR product for SRY was 313 
bp.  
 
Other cells 
 The DLD1 colon cancer cell line was kindly provided by Dr. D Shida (Virginia 
Commonwealth University) and maintained as described (72). The B103 rat neuroblastoma 
cell line lacking endogenous LPA receptors was obtained from Dr. J. Chun (Scripps 
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Research Institute) and cultured in DMEM supplemented with 10% FBS, 100 units/ml 
penicillin and 100 µg/ml streptomycin (107). The rat hepatoma cell line Rh7777 was 
purchased from ATCC and maintained in the same conditions as B103. These cell lines 
were frozen at early passages and used for less than 6 weeks in continuous culture.  
 
RT-quantitative PCR 
 cDNA was synthesized from 1 μg RNA using the ThermoScript™ RT-PCR kit 
(Invitrogen) with random hexamer primers. Quantitative PCR was performed with the pre-
mix TaqMan primer sets on an ABI 7900HT Fast Real-Time PCR System (Applied 
Biosystems, CA). 
 
Recombinant retroviruses and infection of cells  
The Human LPA4 or LPA1 cDNA was inserted between Bam H I and Xho I sites 
upstream of the internal ribosomal entry site of the Moloney murine leukemia retrovirus 
vector pLZRS-EGFP (a gift of J. Chun, Scripps Research Institute) (107). The structure 
and sequences of the cDNAs in these viral constructs were confirmed by restriction 
digestion and automatic sequencing. The Bosc23 packaging cell line (ATCC) was 
transfected with pLZRS-EGFP, pLZRS-EGFP-LPA4 or pLZRS-EGFP-LPA1 using 
Lipofectamine 2000 as described (107). Approximately 20 hours after the beginning of 
transfection, the cells were fed fresh DMEM+10% FBS. Culture supernatants containing 
retrovirus were harvested 48 hours late, cleared by centrifugation and used to infect cells or 
stored at –80°C.  
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The LPA1 and LPA4 cDNAs were also cloned into the pLenti-TOPO lentivirus 
vector (Invitrogen) as an alternate expression system for LPA receptors. The pLenti-
TOPO-LPA1, pLenti-TOPO-LPA4 or pLenti-TOPO-LacZ vector was transfected along 
with packaging plasmids into 293FT cells (Invitrogen) to replicate lentivirus using a 
protocol similar to that for retrovirus generation in Bosc23 cells. MEFs and other cell lines 
in 35-mm dishes at around 50% confluence were incubated for 16-22 hours with 1.5 ml of 
viral supernatants containing 8 μg/ml of Polybrene. The infected cells were harvested 72 
hours after infection. For the cells infected with the retrovirus, EGFP-positive cells were 
isolated by fluorescence-activated cell sorting (FACS). Lentivirus-infected cells were 
selected with blasticidin (10 μg/ml) for 10-14 days and pooled colonies were expanded for 
experiments. When co-expression of LPA1 and LPA4 was desired, the recipient cells were 
infected with the pLenti-TOPO-LPA1 lentivirus followed by infection with the pLZRS-
EGFP-LPA4 retrovirus. 
 
Western Blot  
Cells were lysed in SDS sample buffer or in ice-cold X-100 lysis buffer [1% Triton 
X-100, 50 mM HEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% 
glycerol, 100 mM NaF, 10 mM Na PPi, and protease inhibitor cocktail]. Total cellular 
proteins were resolved by SDS-PAGE, transferred to Immun-Blot membrane 
[poly(vinylidene difluoride)] (BIO-RAD, Hercules, CA), and immunoblotted with 
antibodies following the protocols provided by manufacturers. Immunocomplexes were 
visualized with an enhanced chemiluminescence detection kit (Amersham, Piscataway, 
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NJ), using horseradish peroxidase–conjugated secondary antibodies (Cell Signaling, 
Danvers, MA). 
 
Chemotaxis  
Cell migration was measured in Transwell chambers (BD biosciences, pore size 
8 µm). Transwells were coated with 10 μg/ml collagen 1, and placed in the lower chamber 
containing serum-free DMEM supplemented with LPA or EGF. Cells suspended in serum-
free DMEM containing 0.1% fatty acid-free BSA were added to the upper chamber at 
2.5 × 104 cells/well or 1 × 104 cells/well as indicated. Cells were allowed to migrate for 
4 hr or 6 hr at 37 °C. Non-migrated cells were removed from the top filter surface with a 
cotton swab. Migrated cells attached to the underside of the transwells were washed with 
PBS and stained with crystal violet and counted under a microscope. The invasion of tumor 
cells were measured using Transwells coated with growth factor-reduced Matrigel 
Basement Membrane Matrix (pore size 8 μM, BD biosciences). The assays were performed 
as migration assays except that the cells were incubated for 20-24 hours before termination 
of the experiments. 
 
Generation of GST-Rhotekin-RBD and GST-PAK-PBD fusion proteins 
The cDNA fragments corresponding to the Rho-binding domain (RBD, residue 7-
89) of the mouse Rhotekin (122) or the p21-binding domain (PBD, residues 67-150) of the 
human p21-activated kinase (PAK-1) (123) were cloned between the BamH I and EcoR I 
sites of the pGEX-2T vector (Pharmacia). The plasmids were then transformed into E. coli 
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BL21 to generate GST-Rhotekin-RBD and GST-PAK-PBD fusion proteins. BL21 cells 
transformed with the GST-PAK-PBD construct or transformed with the GST-Rhotekin-
RBD construct were grown at 37 °C and 25 °C, respectively, to the logarithmic phase 
(A600=0.5). Expression of Rhotekin-RBD and PAK-PBD fusion proteins were induced by 
addition of 0.25 mM and 0.5 mM isopropylthiogalactoside for 6 or 3 hours, respectively. 
Cells were pelleted, resuspended in Rhotekin lysis buffer (50 mM Tris-HCl, pH 8.0, 2 mM 
MgCl2, 0.2 mM Na2S2O, 10% glycerol, 20% sucrose, 0.5 mM PMSF, 2 mM dithiothreitol, 
20 µg/ml leupeptin, 80 µg/ml benzamidine, and 40 µg/ml aprotinin) or PAK lysis buffer 
(1% triton, 1 mM EDTA, 1mM PMSF, 15 µg/ml leupeptin, 15 µg/ml aprotinin in PBS), 
and sonicated. Cell lysates were centrifuged at 4°C for 20 min at 7,100 g and the 
supernatants were incubated with glutathione-Sepharose beads for 1 hour at 4°C. Protein 
bound to the beads was washed three times with lysis buffer and the amounts of bound 
GST-fusion proteins were measured by photospectometry and the integrity of the proteins 
was confirmed by Coomassie-stained SDS-PAGE gels.  
 
Rho and Rac Activation Assays  
Activation of Rho and Rac was analyzed by GST pulldown assays (122,123). The 
cells were grown in 10-cm dishes to subconfluence, starved overnight and stimulated with 
LPA or vehicle for the indicated periods of time. The cells were lysed in Magnesium-
containing Lysis Buffer (MLB) (25 mM HEPES, pH 7.5, 150 mM NaCl, 1% NP40, 10% 
glycerol, 10 mM MgCl2, 1 mM EDTA, 1 mM sodium orthovanadate, 10 μg/ml leupeptin, 
10 μg/ml aprotinin, 10 mM NaF). Clarified lysates were incubated for 1 hr at 4 oC with 
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GST-Rhotekin-RBD or GST-PAK-PBD immobilized on glutathione-coupled Sepharose 
beads. Beads were washed in MLB 3 times, eluted with 2 × SDS sample buffer, and 
analyzed by western blotting using monoclonal anti-Rac antibody (BD Biosciences, Cat 
No. 610650) or rabbit anti-RhoA antibody (Santa Cruz Biotechnology, SC-418).  
 
Statistics  
Numerical results from chemotaxis and invasion experiments were presented as 
average cell numbers ± SD. The statistical significances of differences were analyzed using 
Student's t-test where P< 0.05 was considered significant. 
 
Results 
Expression of LPA4 and other LPA receptors in MEFs 
To understand the biological functions of LPA4, we utilized MEFs derived from 
E12.5 to E13.5 embryos to investigate the impact of LPA4 deficiency on cellular responses 
to LPA. We first examined expression of each of LPA receptors in MEFs. RT-PCR 
analysis shows that wild-type MEFs expressed transcripts of LPA1, LPA2, and LPA4 
(Fig.4-1A), but lacked LPA3 or LPA5 mRNA (data not shown). As expected, no LPA4 
transcript was detected in MEFs from X-X- or X-Y embryos. In addition, deletion of lpa4 did 
not lead to any major compensatory changes in expression levels of LPA1 or LPA2 mRNA 
in MEFs as analyzed by RT-PCR and confirmed by RT-qPCR (4-1B).  
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(A) 
                     
(B)  
                                      
Figure 4-1. Expression of LPA4 mRNA in MEFs. (A) Primary MEFs were prepared 
from the 12.5-13.5 embryos. The genotypes of MEFs were determined by PCR as 
described in chapter 3 and the genders determined by PCR amplification of a Y 
chromosome-linked locus SRY. The expression of each LPA receptor mRNA in MEFs was 
analyzed by RT-PCR, which was consistent with the wild type (X+X+, X+Y), knockout (X-
X-, X-Y) or heterozygous (X+X-) genotypes. The size of PCR products was labeled in the 
brackets (bp). (B) RT-qPCR results of LPA1 and LPA2 mRNA in MEFs. 
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Distinct morphology of lpa4 KO MEFs 
Both LPA4-negative and positive MEFs showed morphological characteristics of 
fibroblasts. However, the loss of LPA4 in MEFs changed the cell morphology into a more 
spread and enlarged shape compared to wild type cells (Fig. 4-2). The striking difference 
in morphology between WT and KO MEFs remain evident after MEFs become 
immortalized in culture (Fig. 4-2).  
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Figure 4-2. Morphology of WT and lpa4 KO MEFs. Phase contrast microscopic 
photographs of WT and lpa4 KO MEFs. LPA4-deficient MEFs (KO2.5) showed a more 
flattened morphology compared to WT cells (WT1.3). The striking morphological 
difference was observed in both primary MEFs (upper panels) and immortalized MEF 
lines (lower panels). Bar, 5 μm. 
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Loss of LPA4 potentiates cell migration to LPA, but not to EGF 
Cell morphology and motility are coordinately regulated by LPA signaling through 
intracellular small Rho GTPases (126). The morphological alteration in LPA4 null MEFs 
prompted us to ask whether loss of LPA4 has effect on cell migration, a hallmark cellular 
response to LPA. We compared WT and LPA4 null MEFs for LPA induced cell migration 
using chemotaxis transwell assay. Surprisingly, the LPA4-deficient MEFs exhibited 
remarkably enhanced chemotactic response to LPA (14 fold increase over unstimulated 
cells) (Fig. 4-3) compared to WT cells that only modestly responded to LPA (2.7 fold 
increase). Of interest, the LPA4-defieicent MEFs were also more motile than WT MEFs in 
unstimulated conditions (Fig. 4-3), suggesting that some endogenous LPA may exist or 
accumulate in the cellular microenvironment during the course of the experiments. 
Consistent with the greater basal migratory activity associated with loss of LPA4, more 
lpa4 KO MEFs than WT cells migrated towards EGF (Fig. 4-3). However, the net increase 
by EGF over unstimulated conditions was similar between lpa4 KO and WT MEFs. Thus 
lack of LPA4 specifically sensitized MEFs to LPA-induced chemotaxis. Furthermore, the 
enhancement of LPA-mediated cell migration in the absence of LPA4 was consistent 
among multiple pairs of lpa4 WT and KO MEFs and was observed in both primary MEFs 
and immortalized MEF lines (Fig. 4-4). 
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Figure 4-3. Sensitization of LPA4-deficient MEFs to migratory response to LPA. The 
chemotactic response to LPA (5 μM) or EGF (25 ng/ml) in primary MEFs (WT2.6 and 
KO2.4) were analyzed using collagen-coated transwells. The cells (2.5 × 104 cells/0.5 ml) 
were loaded to the wells and allowed to migrate for 6 hours The migrated cells on the 
underside of transwells were stained with crystal violet and photographed under 
microscope (200 ×) (left panel). The LPA-induced chemotactic migration was quantified 
as detailed in Materials and Methods (right panel). The results were presented as average 
numbers of migrated cells per transwell ± SD of triplicates, representative of three 
independent experiments. *, p = 0.000003. 
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Figure 4-4. Sensitization of LPA4-deficeint cells to LPA-induced cell migration. 
Chemotaxis responses to LPA and EGF were assessed in another independent pair of wild 
type (WT1.3) and KO (KO2.5) primary MEFs and immortalized lines. The results were 
presented as average numbers of migrated cells per transwell or per field (200 ×) ± SD of 
triplicates, representative of three independent experiments. *, p = 0.000007; **, p = 
0.000091. 
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Potentiation of AKT and Rac activation by lpa4 deletion 
To understand functions of LPA4 in cell signaling, we analyzed activation of AKT 
and ERK by LPA in WT and lpa4 KO MEFs. Although LPA-induced ERK 
phosphorylation was similar between WT and KO MEFs, LPA4 deficiency resulted in 
enhancement of AKT phosphorylation at Thr-308 in response to LPA (Fig. 4-5A). The 
potentiating effect of LPA4 deficiency on AKT activation was seen in multiple pairs of WT 
and KO MEFs (data not shown). Furthermore, the enhanced AKT activation in LPA4-
deficient cells was sensitive to LPA1-selective antagonist Ki16425 (124), Gi inhibitor PTX, 
and the PI3K inhibitor LY294002 (Fig. 4-5B), indicating that the prominent AKT 
activation was mediated through the LPA1-Gi-PI3K signaling route in LPA4-deficient cells. 
Moreover, LPA-induced chemotactic migration of LPA4-deficient cells was suppressed by 
Ki16425, PTX or LY294002 but only slightly reduced by an AKT inhibitor (AKTi II) 
(125), suggesting that an LPA1-Gi-PI3K-dependent pathway mediates the robust migratory 
response to LPA in LPA4-deficeint cells. 
We next examined LPA-induced activation of Rac, a well-documented effecter of 
PI3K, and the G12/13 downstream target Rho (26,60,74,91). Rac and Rho mediate cell 
migration in a coordinate fashion. Rac promotes lamellipodia protrusion and forward 
movement while RhoA regulates actomyosin-driven cytoskeleton contraction and 
detachment of the rear of migrating cells (126). LPA-induced Rac activation in fibroblasts 
is generally weak and has been best demonstrated in LPA receptor-overexpressing cells 
(91,127). As shown in Fig. 4-6A, Rac activation in response to LPA was hardly detectable 
in WT MEF line, which correlated with the weak migratory response to LPA in WT cells 
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(Fig. 4-6B). In contrast, LPA evoked prominent increases in Rac-GTP levels in the lpa4 
KO MEF line (Fig. 4-6A).  
In contrast to Rac activation, LPA-induced Rho activation was oppositely affected 
by LPA4 deficiency. As shown in Fig. 4-6A, LPA induced immediate and sustained 
increases in Rho-GTP levels in both WT and lpa4 KO MEF lines as measured by pull 
down with GST-Rhotekin Sepharose beads. However, the magnitude of Rho activation 
induced by LPA was significantly reduced in lpa4 KO cells, suggesting that signaling 
through LPA4 contributes to the overall Rho activation in LPA-stimulated cells. The result 
was consistent with the previous observation that in skin fibroblasts of LPA1 and LPA2 
double knockouts, LPA remained capable of stimulating partial activation of Rho (62), 
which could be attributed to the input of the LPA4 receptor. 
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(A) 
 
 
(B)                                                                (C) 
   
Figure 4-5. Sensitization of LPA4-deficeint MEFs to LPA-induced AKT activation. 
The WT and KO MEF lines were starved in serum-free medium and stimulated with LPA 
(2.5 μM) for the indicated periods of time (A) or in the presence of the LPA1 antagonist 
Ki16425 (10 μM), Gi inhibitor PTX (50 ng/ml) or PI3K inhibitor LY294002 (10 μM) (B). 
Phosphorylation of AKT at Thr308 and ERK at Thr202/Tyr204 of ERK1 and 
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Thr185/Tyr187 of ERK2 were analyzed by immunoblotting with AKT and ERK phospho-
specific antibodies. LPA-induced chemotaxis in the KO MEF line was quantified in the 
absence or presence of the inhibitors described in (C) or AKT inhibitor (AKTi II) (10 μM). 
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 (A)                                                                                    (B) 
 
Figure 4-6. Inhibition of Rho and potentiation of Rac activation by lpa4 deletion: 
correlation with the effect on cell migration. (A) The WT2.6 and KO2.4 cell lines were 
grown to subconfluence, starved in serum-free medium and stimulated with LPA (2.5 μM) 
for the indicated periods of time. The cells were lysed and analyzed for GTP-bound Rho or 
Rac with the GST pulldown assays as described in Materials and Methods. 
Immunoblotting analysis of the total Rho and tubulin was included as protein level 
controls. (B) Inhibition of Rho and potentiation of Rac activation correlated with the effect 
of LPA4 deletion on cell migration. LPA-induced chemotaxis in the WT2.6 and KO2.4 
lines was analyzed and quantified as described in Fig. 4-3. *, p = 0.000042. 
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Inhibition of cell motility by reconstitution of LPA4 
To ascertain whether the enhanced cell migration ability of lpa4 KO cells in 
response to LPA was a direct result from the LPA4 deficiency rather than nonspecific 
effects secondary to gene targeting or MEFs preparation, LPA4 was restored in the KO 
MEFs using the lentivirus-mediated gene transduction. The re-expression of LPA4 in KO 
MEFs was confirmed by western blotting analysis (Fig. 4-7). The LPA-induced migration 
in control virus-infected and LPA4-reconstituted cells was compared. As shown in Fig. 4-8, 
LPA4-reexpressing cells migrated in response to LPA less efficiently than the control 
virus-infected, LPA4-negative cells, confirming that LPA4 functions as a suppressor of 
LPA-dependent cell migration. Furthermore, the inhibition of LPA-dependent cell 
migration by re-expression of LPA4 was accompanied by increased Rho but decreased Rac 
activation induced by LPA (Fig. 4-8). 
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                             KO‐vec                                                        KO‐LPA4 
 
 
Figure 4-7. Reconstitution of LPA4 in LPA4-deficient MEFs. LPA4 expression was 
reconstituted in KO2.5 MEF line by infection with pLenti-LPA4 lentivirus. The expression 
of LPA4 in transduced cells (KO2.5-LPA4) but not in empty virus-infected cells (KO2.5-
vec) was confirmed by immunoblotting with anti-LPA4 antibody (upper panel). Phase 
contrast photographs under microscope of lentivirus transduced control vector or LPA4 
KO2.5 MEFs (lower panel). 
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Figure 4-8. Desensitization of LPA4-deficienct cells to LPA-induced migration by 
reconstitution of LPA4. Expression of LPA4 enhanced Rho but decreased Rac activation. 
LPA-induced Rho and Rac activation in the KO2.5-vec and KO2.5-LPA4 cells was 
analyzed with the GST pull down assays as described in Fig. 4-6 (left panel). The 
chemotactic response to LPA in these cells was analyzed and quantified as described in 
Fig. 4-3 (right panel). *, p = 0.000020. 
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Suppression of LPA-induced cell migration and invasion by LPA4 in colon cancer cells 
To explore the physiological significance of the motility inhibitory effect of LPA4, 
we assessed the role of LPA4 in migration and invasion of human cancer cells. The DLD1 
colon cancer cell line was previously shown to migrate efficiently in response to LPA (72). 
Sub-micromolar concentrations of LPA were sufficient to trigger significant migratory 
response to LPA in DLD1 cells. DLD1 cells expressed LPA1 and LPA2, but lacked LPA3 
or LPA4 mRNA as analyzed by RT-qPCR (Fig. 4-9A). We introduced LPA4 into DLD1 
cells via lentivirus-mediated transduction (Fig. 4-9B). LPA-induced migration in DLD1 
cells was dramatically inhibited by ectopic expression of LPA4 (Fig. 4-9C). LPA was 
effective in stimulating invasion of DLD1 cells through the Matrigel Basement Membrane 
Matrix. The invasion induced by LPA was also significantly suppressed by expression of 
LPA4 (Fig. 4-9C). The inhibitory effect of LPA4 on migration and invasion of DLD1cells 
was not due to interference with endogenous LPA1 or LPA2 receptor expression. In fact, 
following introduction of LPA4, LPA2 mRNA expression was not altered and LPA1 mRNA 
level was actually modestly increased as determined by RT-qPCR (Fig. 4-9B). 
Collectively, these results confirm a general role for LPA4 in negative regulation of 
motility-stimulating activity of LPA in both normal and neoplastic cells. 
 
 
 
 
(A) 
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(B) 
                    
(C) 
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Figure 4-9. Inhibition of LPA-induced migration and invasion of the DLD1 colon 
cancer cells by LPA4. (A) RT-qPCR analysis indicated expression of LPA1 and LPA2 but 
not LPA3 or LPA4 mRNA in DLD1 cells. The mRNA levels were presented as percentages 
relative to GAPDH. (B) Ectopic expression of LPA4 did not decrease expression of 
motility-promoting Edg LPA receptors. Immunoblotting analysis confirmed the expression 
of transduced LPA4 in DLD1-LPA4 cells (left panel). Expression levels of endogenous 
LPA1 and LPA2 mRNAs in DLD1-vec and DLD1-LPA4 cells were compared by RT-
qPCR. The results were normalized on GAPDH and presented as relative percentages with 
the mRNA levels in the control DLD1-vec cells defined as 100%. (C) Expression of LPA4 
inhibited LPA-induced migration and invasion of DLD1 cells. The DLD1-vec and DLD1-
LPA4 cells (2.5 × 104 cells/transwell, 0.2 μM LPA) were allowed to migrate for 6 hr or to 
invade through Matrigel for 24 hr. The cell numbers, LPA concentrations and incubation 
times used in the experiments were determined empirically that yielded maximal or 
submaximal responses. The results of migration and invasion assays were presented as 
detailed in Fig. 4-3. *, p = 0.00003; **, p = 0.0038 (Student’s t test). 
 
 
 
 
 
 
 
85 
 
Antagonism of LPA1-dependent cell migration by LPA4 
Most mammalian cell types express more than one LPA receptor subtypes and 
respond to LPA, making it difficult to connect a cellular response to a specific LPA 
receptor. It is of interest to study the potential cooperation or antagonism among LPA 
receptor subtypes. The rat neuroblastoma cell line B103 offers an ideal model to examine 
the receptor crosstalk due to the absence of endogenous LPA receptors (107). Although it 
was recently shown that there was slight expression of LPA4 mRNA in B103 cells, the cell 
line did not respond to LPA stimulation (60). Therefore, we infected B103 with retrovirus 
carrying LPA4 or LPA1, or with control retrovirus. The transduced, GFP-positive cells 
were isolated by FACS and expanded as stable lines expressing LPA4 or LPA1. In 
agreement with LPA4 being a functional receptor for LPA, LPA4-expressing B103 cells 
underwent neurite retraction and cell rounding upon exposure to LPA (see results in Fig. 2-
9 of Chapter 2), similar to the response seen in LPA1-expressing B103 cells. However, 
only LPA1-expressing cells showed chemotactic response to LPA while the LPA4-
expressing cells and vector control cells did not (Fig. 2-10 of Chapter 2). The observation 
indicates that LPA4 is not capable of driving cell migration in spite of its ability to promote 
Rho-dependent neurite retraction. 
To determine whether LPA4 counteracts the motility-stimulating action of LPA1, 
we co-expressed LPA1 and LPA4 in B103 cells by sequential infection with pLenti-TOPO-
LPA1 lentivirus and pLZRS-EGFP-LPA4 retrovirus. Co-expression of these LPA receptors 
was confirmed by western blotting (Fig. 4-10). Interestingly, LPA4 expression indeed 
inhibited LPA1-mediated migration of B103 cells induced by LPA. The LPA1-dependent 
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migration was inhibited by co-expressed LPA4 by 40%, not as strongly as seen in LPA4-
reexpressing MEFs or LPA4-transduced DLD1 cells probably because the co-expressed 
LPA1 receptor was abundant in the recipient cells (Fig. 4-11). High levels of LPA1 could 
provide a strong motility-promoting drive upon LPA stimulation. In addition, B103 cells 
expressing LPA1 was capable of invading through Matrigel in response to LPA. This effect 
was also significantly attenuated in the cells co-expressing LPA4 (Fig. 4-11). 
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                            B103‐LPA1                                B103‐LPA1 + LPA4 
  
 
Figure 4-10. Stable co-expression of LPA1 and LPA4 results in distinct morphology. 
B103 cells were stably transduced with vector (B103-vec), LPA1 (B103-LPA1) or both 
LPA1 and LPA4 (B103-LPA1 + LPA4). Expression of each receptor was confirmed by 
Western blot analysis (upper panel). Phase-contrast images of B103-LPA1 and B103-
LPA1+LPA4. Note that B103 cells co-expressing LPA1 and LPA4 appeared to adhere to 
each other forming aggregation compared to expression of LPA1 alone (lower panel).   
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Figure 4-11. Antagonism of LPA1-dependent cell migration by LPA4. LPA4 inhibited 
LPA1-mediated migration and invasion when co-expressed with LPA1. B103 cells were 
transduced with vector (B103-vec), LPA1 (B103-LPA1) or both LPA1 and LPA4 (B103-
LPA1 + LPA4). The chemotactic migration induced by LPA in these cells was analyzed 
under the same conditions as in Fig. 2-10 (left panel). The in vitro invasion assays were 
performed with LPA (1 μM) and 1 × 104 cells/transwell coated with Matrigel as described 
in Fig. 4-9 (right panel).  
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DISCUSSION 
Six GPCRs have been identified as cognate LPA receptors to mediate a multitude 
of cellular responses to LPA (5,52-56). It remains elusive why there are multiple receptor 
subtypes for the small lipid mediator. It is even more intriguing that these LPA receptors 
fall into structurally distant families sharing little amino acid identities. LPA1-3 and the 
receptors for the closely related S1P (S1P1-5) belong to the Edg family (26,58). The LPA1 
receptor is most widely distributed and is involved in initiation of neuropathic pain and 
promotion of pulmonary and renal fibrosis (64-66). LPA3, a receptor subtype expressed in 
the uterus, seems to be important for embryo implantation and spacing (83). LPA2 and 
LPA3 receptors are overexpressed in a variety of human malignancies including cancers of 
the colon, ovary, breast and thyroid (71,73,82,128). The LPA4 receptor is not only 
structurally distant from the LPA1-3 receptors of the Edg family, but also couple to different 
categories of G proteins. It is linked to Gq, G12/13 and probably Gs, but not Gi whereas 
LPA1-3 receptors all couple to Gi (26). The differences in receptor structure and G protein 
partnership between the Edg LPA receptors and the LPA4 receptors prompted us to study 
biological functions of LPA4 by developing knockout mice. While the interim 
characterization has not revealed apparent abnormalities in LPA4-deficient mice, the truly 
LPA4-negative MEFs isolated from LPA4-deficient embryos have allowed us to evaluate 
the role of LPA4 in LPA signal transduction and migratory response to LPA. The results 
presented in the current work clearly demonstrate that knockout of lpa4 sensitizes the cells 
to LPA-induced migration. In WT cells, the presence of LPA4 may thus serve as a barrier 
preventing overreaction to LPA. The specific role of LPA4 in limiting LPA-induced cell 
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motility was confirmed by LPA4 reconstitution experiment showing reexpression of LPA4 
desensitizes KO MEFs to LPA-induced migration. Moreover, heterologous expression of 
LPA4 in rat neuroblastoma and human colon cancer cell lines suppressed LPA-triggered 
cell migration and invasion, antagonizing the motility-promoting effect of the LPA1 
receptor. It will be of interest to examine in the future whether LPA4 expression was 
deregulated in human tumors contributing to the invasive and metastatic potential of 
cancer cells. 
  The discovery of negative regulation of LPA-dependent migration by LPA4 
provides novel insights into the crosstalk among the multiple LPA receptors that are 
frequently co-expressed in mammalian cells. We have recently described that LPA induced 
cyclooxygenase-2 expression in ovarian cancer cells through a mechanism requiring LPA1, 
LPA2, and LPA5 receptors (24). Integration of signals from multiple LPA receptors may be 
necessary for the optimal activation of LPA-mediated responses. There are many other 
examples of functional complementation or redundancy among LPA receptors 
(19,24,107,129). However, the functional antagonism between LPA receptors has rarely 
been demonstrated (107). The opposing effects of LPA1 and LPA4 receptors on LPA-
induced cell migration and invasion described in the current work represent such an 
example of functional inhibition among LPA receptors. This inhibitory crosstalk is likely 
critical to ensure physiologically appropriate responses to LPA. It is yet to be determined 
whether LPA4 also negatively regulate some other biological functions of LPA. In B103 
cells, however, LPA4 mimics LPA1 in promoting neurite retraction and cell rounding, 
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suggesting that LPA4 is indeed a functional LPA receptor that mediates certain cellular 
effects of LPA while inhibiting others, depending on signaling pathways involved.  
Although the molecular mechanism for LPA4 downregulation of cell motility 
remains to be fully elucidated, our results provide some clues to the potential players in the 
process. As discussed above, the cell motility is tightly controlled by activities of Rho and 
Rac in a coordinate fashion (126).The balance of Rho and Rac activities are critical 
determinants of cell movement (126). LPA4 contributes to the total Rho activation in 
MEFs likely through G12/13 (59.60). Our results demonstrate that loss of LPA4 decreased 
LPA-stimulated Rho activation as anticipated but simultaneously enhanced LPA-induced 
Rac activation. The observation suggests that LPA4 may exert its inhibitory effect on cell 
migration through increasing the relative ratios of active Rho versus active Rac in LPA-
treated cells. LPA4 seems to interfere with activation of Rac by inhibiting PI3K. This is 
supported by the fact that LPA4 expression attenuates other PI3K effectors such as AKT. 
In addition to this possibility, Rac activation could be inhibited by excessive Rho activity 
in WT cells as has been proposed in other cell systems (95,130,131). It is also possible that 
LPA4 directly desensitizes the LPA1 receptor that is known to stimulate Rac activation 
through Gi (91). The role of LPA4 in negative control of cell motility is reminiscent of 
S1P2, one of S1P receptors, that has been shown to inhibit cell migration (95,131,132). 
Similar to LPA4, S1P2 is coupled to G12/13 and Gq, but not Gi (58). Several studies suggest 
the negative effect of S1P2 on cell motility is attributed to G12/13-mediated Rho activation 
(95,131,132). Activation of Rho in the absence of appropriate Rac input seems to be 
sufficient to confer inhibition of cell motility (95,130,131).  
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It is not surprising that the LPA4-deficient mice do not show obvious phenotypic 
abnormalities at least at early ages. LPA1 and LPA2 knockouts are also dispensable from 
normal development and physiology (63,79). However, these knockout animals have 
proved to be valued models to link LPA signaling to pathophysiological processes (64-66). 
The backup and/or redundant receptor subtypes of LPA may suffice to compensate for the 
loss of individual LPA receptors in vivo. Alternatively, LPA, as one of phospholipids 
present in the circulation and tissues, may not be the only or rate-limiting mediator 
physiologically required in vivo. Instead, LPA signaling may be more critical in 
pathophysiological settings when levels of the lipid mediator are locally and temporally 
altered. Recent studies of LPA1-deficeint mice demonstrated involvement of LPA1 in 
abnormal wound healing and fibrosis formation (64,65) supports a major role for this LPA 
receptor subtype in chemotactic recruitment of fibroblasts to the site of wound. In light of 
the opposing effects of LPA4 and LPA1 on migratory response of various cell types to 
LPA, it is interesting to study roles of LPA4 in wound healing and other pathophysiological 
conditions using LPA4-deficient mice developed in the current study. 
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CHAPTER 5: GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
Major Findings and Achievements 
 The present study aimed to gain better understanding of LPA4, one of the newly 
identified LPA receptors. The three new LPA receptors (LPA4-6) are structurally diverse 
from the well defined Edg LPA receptors. Little is known about their expression and roles 
in LPA signal transduction, health and diseases. Comprehensive knowledge of LPA4 will 
provide clues to the physiological roles of this new subclass of LPA receptors. Our results   
confirmed the identity of LPA4 as a functional LPA receptor which mediates a subset of 
responses to LPA. Functional studies of LPA4 demonstrate that LPA4 couples primarily to 
G12/13, which activates the Rho-ROCK pathway and actomyocin-driven cytoskeleton 
remodeling. Different from the Edg LPA receptors, LPA4 fails to activate Gi-mediated 
ERK and PI3K pathways and the subsequent migratory response to LPA. To delineate 
physiological functions of LPA4, we have developed lpa4 knockout mice. Interim analysis 
of lpa4 knockout mice showed that LPA4 is not required for embryonic development or 
fertility. The LPA4-deficient mice are physiologically normal and are grossly 
indistinguishable from their wild type littermates. However, these animals provide a useful 
cell model to study the effect of LPA4 deficiency on LPA signal transduction and 
responses to LPA. Our analysis demonstrated a novel function of LPA4 in suppressor of 
cell motility in contrast to the Edg LPA receptors that all positively regulate cell migration. 
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Deletion of lpa4 dramatically sensitizes cells to LPA-induced cell migration. On the other 
hand, overexpression of LPA4 inhibits LPA-mediated cell migration and tumor cell 
invasion. When coexpressed with the motility-stimulating LPA1 receptor, LPA4 attenuates 
the LPA1-driven cell migration and invasion, highlighting functional antagonism between 
the two subtypes of LPA receptors. These results constitute the first evidence for the 
existence of negative LPA receptors. The crosstalk among LPA receptors may be critical 
to ensure physiologically appropriate responses to LPA. Mechanistic studies of lpa4 
knockout and “knock-in” MEFs further demonstrated that LPA4 inhibits activation of 
PI3K-dependent activation of AKT and Rac, an effect that could suppress cell motility. 
 
Potential Mechanism for Negative Regulation of PI3K by LPA4 
LPA4 does not couple to Gi and Gi-dependent activation of PI3K. However, it 
remains to be determined how expression of LPA4 negatively impinges on LPA-induced 
activation of PI3K and the downstream effectors AKT and Rac. One possibility is that 
LPA4-triggered activation of the Gq-PLCβ competes with Gi-PI3K for their common 
substrate PIP2. Since LPA4 couples to Gq only, loss of LPA4 should allow PIP2 
accumulation for PI3K to convert to PIP3, which favors activation of the downstream 
targets AKT and Rac. This possibility could be evaluated by supplying excessive 
exogenous PIP2 or inhibition of PLCβ with specific pharmacological inhibitors. Another 
possible mechanism for LPA4 negative regulation of PI3K is desensitization of the Edg 
LPA receptors through physical interactions such as hetero-dimerization or other types of 
complexion. It has been reported that LPA receptors have tendency to form homo- and 
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hetero-dimers with each other, with S1P receptors and even with certain unrelated GPCRs 
(133). So it is likely that LPA4 may form hetero-dimers with the PI3K-stimulating LPA1-3 
receptors. As such, the presence of LPA4 will interfere with LPA-dependent activation of 
AKT and Rac. We will examine the possibility of physical interactions between LPA4 and 
the Edg LPA receptors by co-immunoprecipitaion and the LacZ complementation assays 
(133). 
 
Role of LPA4 in Prevention of Cancer Metastasis 
There is substantial evidence that LPA plays a role in tumor cell invasion and 
metastasis. As stated before, the LPA-producing enzyme ATX was originally identified as 
a tumor cell motility-stimulating factor (39). Overexpression of ATX in Ras-transformed 
3T3 cells enhances metastasis of xenografts in nude mice (134). In further support of a role 
of LPA signaling in cancer metastasis, expression of LPA1, the major chemoattractant 
receptor for LPA, enhances bone metastasis of breast cancer cell lines in nude mice (135). 
Conversely, downregulation of LPA1 expression or blockade of LPA1 with a selective 
antagonist (Ki16425) inhibited metastasis of these cells to the bone (135,136). If LPA4 is a 
suppressor of motility of both normal and neoplastic cells, LPA4 could be downregulated 
in human cancers and their metastasis. We are currently testing this possibility by profiling 
LPA4 expression in various human cancers and their normal tissue counterparts. At 
present, we know that LPA4 expression is reduced at least in ovarian cancer cell lines 
compared to normal ovarian epithelial cells. 
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LPA4 Knockout: Lack of Phenotypes or Lack of Thorough Analysis 
In spite of lack of apparent phenotypes, we have used the cells from the lpa4 KO 
mice to uncover a previously unrecognized function of LPA4. It is unknown why loss of 
LPA4 and its inhibitory effect on cell motility does not culminate in any major 
physiological defects in mice at least at early ages. Similarly, lpa1 and lpa2 knockouts are 
also dispensable from normal development and physiology despite the significant deficit in 
cell signaling associated with deletion of lpa1 or lpa2 (63,79). However, these lpa1 
knockout animals have proved to be valued models to link LPA signaling to many 
pathophysiological processes (64-66). The phenotypes of LPA receptor-deficient mice are 
compatible with involvement of LPA signaling in pathophysiological circumstances. 
Hence we will further explore the phenotypes of LPA4-deficient mice under stress as has 
been done with lpa1 knockout mice (64,65). 
Based upon the crucial roles of the PI3K- AKT pathway in oncogenesis, deletion of 
lpa4 and its inhibitory effect on PI3K may increase the susceptibility of the LPA4-deficient 
mice to spontaneous or carcinogen-induced tumorigenesis. We have indeed observed 
development of various spontaneous tumors in lpa4 KO and heterozygous mice, but not in 
their wild type littermates. Further analysis involving more animals and chemical 
carcinogens will help provide definitive answer to whether loss of LPA4 leads to increased 
susceptibility to tumorigenesis.  
 
LPA4 as a Therapeutic Target 
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As addressed earlier, LPA4 likely functions as a negative regulator of migration, 
invasion and metastasis of tumor cells. There is also preliminary evidence that LPA4 may 
act as a tumor suppressor. As a cell surface GPCR, LPA4 is a highly druggable target. It is 
well known that more than half of medicines in the current use target GPCRs. It is possible 
to identify LPA4-specific agonists that do not cross react with the structurally distant Edg 
LPA receptors. A sensitive and robust GPCR activation assay such as the recently 
developed TangoTM assay could be used to screen LPA analogs (137). The LPA4-selective 
agonists may be appealing chemoprevention and anti-neoplastic agents if the tumor-
suppressive function of LPA4 is confirmed.   
 
 
 
 
.  
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